Schedule Update - effective 1 July 2010 (text extract)

This is the text extract for Schedule Update - effective 1 July 2010, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 July 2010 Cumulative for May, June and July 2010 Section H for April, May, June and July 2010

Contents

Summary of PHARMAC decisions effective 1 July 2010 ................................. 3 Topical acne treatment subsidised ................................................................. 6 Clomiphene citrate tablets ............................................................................ 6 New strength of lopinivar with ritonavir subsidised ...................................... 7 Antiretrovirals – amended Special Authority criteria...................................... 7 Potassium iodate tablets – new listing .......................................................... 7 Danthron with poloxamer – new listing ........................................................ 7 Amlodipine – temporary listing of Norvasc ................................................... 8 Transdermal oestrogen hormone replacement therapy – Special Authority amendment .................................................................... 8 Influenza vaccine – season extended ............................................................. 8 Domperidone – full funding and removal of Special Authority ..................... 9 Tolcapone – prescriber restriction removed ................................................... 9 Trastuzumab – Special Authority amended ................................................... 9 Octreotide – widened access ....................................................................... 10 Named Specialists for antiretrovirals ........................................................... 10 Diaphragms – rationalisation of products .................................................. 11 News in Brief ............................................................................................... 11 Tender News ................................................................................................ 12 Looking Forward ......................................................................................... 12 Sole Subsidised Supply products cumulative to July 2010 ........................... 14 New Listings ................................................................................................ 21 Changes to Restrictions ............................................................................... 24 Changes to Subsidy and Manufacturer’s Price............................................. 35 Changes to Brand Name ............................................................................. 40 Changes to Sole Subsidised Supply ............................................................. 40 Delisted Items ............................................................................................. 41 Items to be Delisted .................................................................................... 44 Section H changes to Part I ......................................................................... 49 Section H changes to Part II ........................................................................ 49 Section H changes to Part IV ....................................................................... 62 Index ........................................................................................................... 63

Summary of PharmaC decisions

effeCtive 1 July 2010 New listings (pages 21-23) • Potassium iodate (NeuroKare) tab 268 µg (150 µg elemental) • Danthron with poloxamer (Pinorax) oral liq 25 mg with poloxamer 200 mg per 5 ml – only on a prescription – only for the prevention or treatment of constipation in the terminally ill • Multivitamins (paediatric Seravit) powder, 200 g OP – Special Authority – Retail pharmacy • Vitamins (MultiADE) tab (BPC cap strength) • Amlodipine (Norvasc) tab 5 mg and 10 mg • Tretinoin (ReTrieve) crm 0.5 mg per g OP – maximum of 50 g per prescription • Coal tar (Midwest) soln BP, 200 ml – only in combination • Oestradiol (Estradot 50 mcg) TDDS 50 µg per day – Higher subsidy with Special Authority, no more than 2 patches per week, only on a prescription • Clomiphene citrate (Serophene) tab 50 mg • Lopinavir with ritonavir (Kaletra) tab 100 mg with ritonavir 25 mg – Special Authority – Hospital pharmacy [HP1] • Fluoxetine hydrochloride (Fluox) cap 20 mg – 84 tablet pack • Flumetasone pivalate (Locacorten-Vioform ED’s) ear drops 0.02% with clioquinol 1% • Glycerol (healthE) liquid, 2,000 ml – only in combination, only in extemporaneously compounded oral liquid preparations • Protein supplement (Resource Beneprotein) powder, 227 g OP – Special Authority – Hospital pharmacy [HP3] • Aminoacid formula with minerals without phenylalanine (Metabolic Mineral Mixture) powder, 100 g OP – Special Authority – Retail pharmacy Changes to restrictions (pages 24-34) • Clotrimazole (Clomazol) vaginal crm 1% with applicators – amended presentation • Hormone replacement therapy – systemic – amended Special Authority criteria • Clomiphene citrate – removal of Retail pharmacy-Specialist and only a prescription for a female patient restrictions • Dapsone (Dapsone) tab 25 mg and 100 mg – addition of Section 29 • Antiretrovirals – amended Special Authority criteria • Influenza vaccine (Fluvax, Influvac, Vaxigrip) inj – extended season • Domperidone (Motilium) tab 10 mg – removal of Additional subsidy by Special Authority for manufacturers price • Tolcapone (Tasmar) tab 100 mg – removal of Retail pharmacy-Specialist prescription

Summary of PharmaC decisions – effective 1 July 2010 (continued) • Octreotide (somatostatin analogue) (Hospira, Sandostatin) inj 50 µg per ml, 1 ml, 100 µg per ml, 1 ml, and 500 µg per ml, 1 ml, and (Sandostatin LAR) inj LAR prefilled syringe 10 mg, 20 mg and 30 mg – amended Special Authority criteria • Trastuzumab (Herceptin) inj 150 mg vial and 440 mg vial, and (Baxter) inj 1 mg for ECP – amended Special Authority criteria Decreased subsidy (pages 35-49) • Pantoprazole (Dr Reddy’s Pantoprazole) tab 20 mg and 40 mg • Bisacodyl (Lax-Tabs) tab 5 mg • Aspirin (Ethics Aspirin EC) tab 100 mg • Dextrose with electrolytes (Pedialyte – Bubblegum, Fruit and Plain) soln with electrolytes • Metroprolol succinate (Betaloc CR and Metoprolol – AFT CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg • Bendrofluazide (Neo-Naclex) tab 2.5 mg and 5 mg • Spironolactone (Spirotone) tab 25 mg and 100 mg • Fusidic acid (Foban) crm 25 and oint 2% • Hydrocortisone with miconazole (Micreme H) crm 1% with miconazole nitrate 2% • Cetomacrogol (PSM) crm BP • Coal tar (PSM) soln BP • Clotrimazole (Clomazol) vaginal crm 1% with applicators and vaginal crm 2% with applicators • Testosterone undecanoate (Andriol Testocaps, Panteston) cap 40 mg • Cabergoline (Arrow-Cabergoline) tab 0.5 mg, 2 and 8 tab pack sizes • Cefaclor monohydrate (Ranbaxy-Cefaclor) grans for oral liq 125 mg per 5 ml • Phenoxymethylpenicillin (Penicillin V) (AFT) grans for oral liq 250 mg per 5 ml • Ibuprofen (Fenpaed) oral liq 100 mg per 5 ml • Aspirin (Aspec 300) tab EC 300 mg • Aspirin (Ethics Aspirin) tab dispersible 300 mg • Fluoxetine hydrochloride (Fluox) tab dispersible 20 mg, scored • Fluoxetine hydrochloride (Fluox) cap 20 mg • Paroxetine hydrochloride (Loxamine) tab 20 mg • Ropinirole hydrochloride (Ropin) tab 0.25 mg, 1 mg, 2 mg and 5 mg • Cisplatin (Baxter) inj 1 mg for ECP • Gemcitabine hydrochloride (Gemcitabine Ebewe) inj 200 mg and 1 g, and (Baxter) inj 1 mg for ECP • Docetaxel (Baxter) inj 1 mg for ECP

Summary of PharmaC decisions – effective 1 July 2010 (continued) • Mitozantrone (Mitozantrone Ebewe) inj 2 mg per ml, 10 ml, and (Baxter) inj 1 mg for ECP • Loratadine (Loraclear Hayfever Relief) tab 10 mg, and (Lorapaed) oral liq 1 mg per ml • Salbutamol (Salapin) oral liq 2 mg per 5 ml • Glycerol (PSM) liquid increased subsidy (pages 37-38) • Phenytoin sodium tab 50 mg (Dilantin Infatab), cap 30 mg and 100 mg (Dilantin), and oral liq 30 mg per 5 ml (Dilantin) • Domperidone (Motillium) tab 10 mg • Oral supplement 1kcal/ml (Sustagen Hospital Formula) powder (chocolate) and powder (vanilla), 900 g OP • Oral elemental feed 1kcal/ml (Vivonex TEN) powder (unflavoured), 80.4 g OP

6 Pharmaceutical Schedule - Update News

Topical acne treatment subsidised

ReTrieve (tretinoin) cream (0.5 mg per g) 50 g OP will be fully subsidised on the Pharmaceutical Schedule from 1 July 2010. ReTrieve will have a maximum quantity restriction of 50 g per prescription. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris, primary grades I-III in which comedones, papules and pustules predominate. Tretinoin cream is not

recommended as mono-therapy in cases of severe pustular and deep cystic nodular varieties (acne conglobata).

Clomiphene citrate tablets

An alternative brand of clomiphene citrate 50 mg tablets will be subsidised from 1 July 2010. Serophene, Merck Serono's brand of clomiphene citrate, will be fully subsidised and will be supplied in packs of 10. In addition the prescribing restrictions of “Retail pharmacy-Specialist” and “Only on a prescription for a female patient” will be removed from 1 July 2010. The Phenate brand of clomiphene citrate is now out of stock.

Pharmaceutical Schedule - Update News

New strength of lopinavir with ritonavir subsidised

A paediatric strength of Kaletra (lopinavir 100 mg with ritonavir 25 mg) tablets will be subsidised from 1 July 2010. The Special Authority that applies to the other presentations of lopinavir with ritonavir also applies to this paediatric strength.

Antiretrovirals – amended Special Authority criteria

From 1 July funding of antiretrovirals has been widened to include prophylaxis for non-occupational exposure to a known HIV source. Also the renewal criteria for percutaneous exposure has been amended to permit more than one renewal application.

Potassium iodate tablets – new listing

The iodine supplement, NeuroKare (potassium iodate 268 µg (150 µg elemental)) tablets, will be fully subsidised without any restrictions from 1 July 2010. Potassium iodate is used in the synthesis of the thyroid hormones, triiodothyronine (T3) and thyroxine (T4), both of which are required for normal growth and development of the brain.

Danthron with poloxamer – new listing

Danthron with poloxamer oral liquid 25 mg, with poloxamer 200 mg per 5 ml (Pinorax), will be listed and fully subsidised on the Pharmaceutical Schedule from 1 July 2010. The following prescribing note has been applied to the listing – “Only for the prevention or treatment of constipation in the terminally ill”. The listing of this medicine gives further treatment options for the terminally ill. Danthron with poloxamer oral liquid (Codalax) was discontinued in 2007 and PHARMAC has been seeking an alternative supplier since then. Pinorax recently obtained provisional consent (Section 23) from Medsafe for distribution in New Zealand. Pinorax Forte (Danthron with poloxamer oral liquid 75 mg, with poloxamer 1 g per 5 ml) will be fully subsidised in the near future.

Pharmaceutical Schedule - Update News

Amlodipine – temporary listing of Norvasc

Apo-Amlodipine 5 mg and 10 mg tablets are expected to go out-of-stock within the coming month. As a result PHARMAC will temporarily list Norvasc 5 mg and 10 mg tablets to cover this out-of-stock situation. Sole Supply Status and Hospital Supply Status will be suspended on ApoAmlodipine until further notice. Monthly pharmacist annotated Close Control will not be applied to the dispensing of amodipine tablets at this time.

Transdermal oestrogen hormone replacement therapy – Special Authority amendment

Transdermal oestrogen hormone replacement therapy currently attracts additional subsidy via a Special Authority that can only be applied for by certain specialist groups and general practitioners. From 1 July 2010 the Special Authority will be amended to allow all relevant practitioners the ability to apply for additional subsidy via Special Authority. Additionally, patients receiving subsidised somatropin, who also use hormone replacement therapy, will be eligible for the additional subsidy via Special Authority.

Influenza vaccine – season extended

The Ministry of Health recently decided to extend the influenza vaccination season. The vaccine will continue to be subsidised for eligible people until supplies are exhausted. The access criteria for influenza vaccine remain unchanged.

Pharmaceutical Schedule - Update News

Domperidone – full funding and removal of Special Authority

From 1 July 2010 the Special Authority for manufacturer’s price that applies to domperidone 10 mg tablets (Motilium) will be removed and domperidone 10 mg tablets will become fully funded for all patients.

Tolcapone – prescriber restriction removed

The prescriber restriction applying to the subsidy for tolcapone 100 mg tablets (Tasmar) will be removed from 1 July 2010. The “Retail pharmacy-Specialist Prescription, Specialist must be a neurologist, geriatrician or general physician” restriction will be removed. The restriction was in line with previous Medsafe requirements for the prescribing of tolcapone under Section 23 of the Medicines Act 1981, which no longer apply as this medicine now has full regulatory consent. Tolcapone is indicated for use in combination with levodopa/benserazide and levodopa/carbidopa in Parkinson's disease, including both fluctuating and non-fluctuating patients.

Trastuzumab – Special Authority amended

From 1 July 2010 the Special Authority criteria for access to subsidised trastuzumab in the Pharmaceutical Schedule will be amended to allow access to DHB funding for treatment of up to 12 months for patients with HER 2 positive early breast cancer. This decision will result in an administrative and funding shift from the Ministry of Health to PHARMAC and the District Health Boards providing one consistent funding mechanism for all subsidised trastuzumab treatment. The new administrative and funding arrangements will deliver administrative efficiencies to the health sector and improve data collection.

10 Pharmaceutical Schedule - Update News

Octreotide – widened access

The Special Authority criteria for octreotide will be widened from 1 July 2010. In summary the Special Authority criteria for octreotide (somatostatin analogue) injection 50 µg per ml, 1 ml, 100 µg per ml, 1 ml and 500 µg per ml, 1 ml; LAR 10 mg prefilled syringe, LAR 20 mg prefilled syringe and LAR 30 mg prefilled syringe will be widened to include: • The treatment of nausea and vomiting in patients with malignant bowel obstruction where treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics have failed; and • The treatment of acromegaly in patients unwilling or unable to undergo surgery and/or radiotherapy or for an interim period until radiotherapy becomes fully effective. Octreotide is not currently registered by Medsafe for the treatment of nausea and vomiting in patients with malignant bowel obstruction. As such, clinicians will need to comply with Section 25 of the Medicines Act if prescribing octreotide for this use.

Named Specialists for antiretrovirals

Last month we published a list of currently approved named Specialists that the Ministry of Health has approved to prescribe HIV antiretroviral agents in New Zealand. This list contained a number of prescribers who are no longer approved. The following have been removed and are no longer approved by the Ministry of Health to prescribe antiretrovirals: • Dr Anthony Neil Graham – Tauranga • Dr Elizabeth Spellacy - Tauranga • Dr Kenneth Romeril - Wellington • Dr Stephen Delany - Nelson • Dr Robin Corbett – Christchurch • Dr Charles Beresford – Dunedin • Dr Deborah Williams - Dunedin

Pharmaceutical Schedule - Update News

Diaphragms – rationalisation of products

Janssen-Cilag has notified that the Ortho Coil brand of diaphragms is being discontinued internationally. The Ortho All Flex diaphragm range will remain on the market but will be rationalised to four sizes with the 65, 70, 75 and 80 mm sizes only to be available. Additionally the latex in the current Ortho All Flex product is to be changed to a silicone based product. Both latex and silicone products will be funded until the supply of the latex product is exhausted.

News in Brief

• The registration for the Link brand of dapsone tablets 25 mg and 100 mg has lapsed, so it is now being supplied under Section 29 of the Medicines Act 1981 as it is an unregistered medicine. • Mylan New Zealand Limited has notified of its intention to discontinue its brand of piroxicam (Piram-D) dispersible tablets 10 mg and 20 mg in the next few months. Mylan expects to run out of both presentations in August 2010. PHARMAC has been unable to secure an alternative supply of piroxicam. • Mylan New Zealand Limited has also notified of its intention to discontinue its brand of labetalol (Hybloc) tablets 400 mg in the next few months. Mylan expects to run out of stock in July 2010. PHARMAC has been unable to secure an alternative supply of labetalol 400 mg tablets. • Roche Products (New Zealand) Ltd has notified of its intention of discontinue midazolam (Hypnovel) tab 7.5 mg. This is a global discontinuation. Roche is expected to have stock in New Zealand until approximately June 2011.

tender News

Sole Subsidised Supply changes – effective 1 August 2010

Chemical Name Chlorhexidine gluconate Crotamiton Lamivudine Lamivudine Megestrol acetate Pregnancy tests – hCG urine Presentation; Pack size Handrub 1% with ethanol 70%; 500 ml Crm 10%; 20 g OP Oral liq 10 mg per ml, 240 ml OP Tab 150 mg; 60 tab Tab 160 mg; 30 tab Cassette; 40 test OP Sole Subsidised Supply brand (and supplier) healthE (Jaychem) Itch-Soothe (AFT) 3TC (GSK) 3TC (GSK) Apo-Megestrol (Apotex) Innovation hCG One Step Pregnancy Test (Inverness Medical)

looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Decision for implementation 1 august 2010 • Atorvastatin tab 10 mg (Lorstat 10), 20 mg (Lorstat 20), 40 mg (Lorstat 40) and 80 mg (Lorstat 80) – new listing • Adalimumab (HumiraPen) inj 40 mg per 0.8 ml prefilled pen and (Humira) inj 40 mg per 0.8 ml prefilled syringe – amended Special Authority criteria • Dietitian prescribing – special foods and potentially other products • Hydrocortisone with cinchocaine (Proctosedyl) oint and suppos – new listing • Insulin glargine (Lantus) inj 100 u per ml, 3 ml and 10 ml (Lantus SoloStar) inj 100 u per ml, 3 ml disposable pen – removal of Special Authority and addition of endorsment • Insulin glulisine (Apidra) inj 100 u per ml, 10 ml and (Apidra SoloStar) inj 100 u per ml, 3 ml x 5 - new listing • Ketone blood ß- ketone electrodes (Optium Blood Ketone Test Strips) test strip – removal of endorsement criteria and addition of maximum of 20 strips per prescription • Levonorgestrel (Jadelle) subdermal Implant (2 x 75 mg rods) – new listing • Povidone iodine (Betadine) oint 10% - subsidy increase • Quetiapine (Dr Reddy’s Quetiapine) tab 25 mg, 100 mg, 200 mg and 300 mg – new listing

Possible decisions for implementation 1 august 2010 (continued) • Removal of the ‘Hospital Pharmacy [HP1]’ restriction from the Pharmaceutical Schedule • Removal of the ‘Hospital Pharmacy [HP3]’ restriction from all products other than Special Foods • Removal of the Wholesale Supply Order mechanism, with affected products becoming available on Practitioner’s Supply Order • Sodium nitroprusside (Ketostix) test strip – maximum of 20 strips per prescription • Triclosan (healthE) soln 1%, 500 ml – new listing – no more than 500 ml per prescription, only for patient identified with MRSA prior to elective surgery in hospital, or staphylococcus aureus infection • Antiretrovirals - widening of access to allow four fully funded antiretrovirals

Sole Subsidised Supply Products – cumulative to July 2010

Generic Name

Acarbose Acetazolamide Allopurinol Amantadine hydrochloride Amoxycillin

Presentation

Tab 50 mg & 100 mg Tab 250 mg Tab 100 mg & 300 mg Cap 100 mg Grans for oral liq 250 mg per 5 ml Drops 125 mg per 1.25 ml Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab amoxycillin 500 mg with potassium clavulanate 125 mg Crm 500 g Tab 50 mg & 100 mg Inj 600 µg, 1 ml Tab 500 mg Tab 10 mg Inj 1 mega u Scalp app 0.1% Tab 200 mg Tab 50 mg Eye drops 0.2% Crm, aqueous, BP Lotn, BP Inj 100 iu per ml, 1 ml Cap 0.25 µg & 0.5 µg Tab eff 1.7 g (1 g elemental) Inj 50 mg Inj 500 mg & 1 g Inj 750 mg & 1.5 g Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 10 mg Oral liq 1 mg per ml Eye oint 1%

Brand Name Expiry Date*

Glucobay Diamox Apo-Allopurinol Symmetrel Ospamox Ospamox Paediatric Drops Curam Curam Synermox AFT Atenolol Tablet USP AstraZeneca Arrow-Azithromycin Pacifen Sandoz Beta Scalp Fibalip Bicalox AFT healthE API Miacalcic Airflow Calsource Calcium Folinate Ebewe Hospira Zinacef Cefalexin Sandoz Cefalexin Sandoz Zetop Cetirizine-AFT Chlorsig 2011 2011 2012 2012 2012 2012 2011 2012 2011 2011 2011 2012 2011 2012 2011 2011 2011 2011 2012 2011 2012 2012 2011 2011 2011 2012 2011 2012

Amoxycillin clavulanate

Aqueous cream Atenolol Atropine sulphate Azithromycin Baclofen Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Bezafibrate Bicalutamide Brimonidine tartrate Calamine Calcitonin Calcitriol Calcium carbonate Calcium folinate Cefazolin sodium Cefuroxime sodium Cephalexin monohydrate Cetirizine hydrochloride Chloramphenicol

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to July 2010

Generic Name

Chlorhexidine gluconate Ciclopiroxolamine Ciprofloxacin Citalopram Clobetasol propionate

Presentation

Soln 4% Nail soln 8% Tab 250 mg, 500 mg & 750 mg Tab 20 mg Crm 0.05% Oint 0.05% Scalp app 0.05% Tab 500 µg & 2 mg TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg Crm 1% Tab 50 mg Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs Nasal spray 10 µg per dose Inj 50%, 10 ml Tab EC 25 mg & 50 mg Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Tab 50 mg with total sennosides 8 mg Oint BP Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml

Brand Name Expiry Date*

Orion Batrafen Rex Medical Arrow-Citalopram Dermol Dermol Dermol Paxam Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Dixarit Catapres Clomazol Nausicalm Siterone Ginet 84 Desmopressin-PH&T Biomed Diclofenac Sandoz Voltaren Ophtha Voltaren Voltaren DHC Continus Dilzem Cardizem CD Pytazen SR Laxsol AFT Clexane Comtan E-Mycin E-Mycin E-Mycin 2011 2012 2011 2011 2012

Clonazepam Clonidine

2011 2012

Clonidine hydrochloride

2012

Clotrimazole Cyclizine hydrochloride Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dextrose Diclofenac sodium

2011 2012 2012 2011 2011 2011 2012 2011

Dihydrocodeine tartrate Diltiazem hydrochloride

2013 2011

Dipyridamole Docusate sodium with sennosides Emulsifying ointment Enoxaparin sodium (low molecular weight heparin) Entacapone Erythromycin ethyl succinate

2011 2013 2011 2012 2012 2012 2011

Sole Subsidised Supply Products – cumulative to July 2010

Generic Name

Ethinyloestradiol Etidronate disodium Felodipine Finasteride Flucloxacillin sodium

Presentation

Tab 10 µg Tab 200 mg Tab long-acting 5 mg Tab long-acting 10 mg Tab 5 mg Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Inj 50 mg Tab 10 mg Eye drops 0.1% Metered aqueous nasal spray, 50 µg per dose Tab 40 mg Cap 100 mg, 300 mg & 400 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg & 10 mg

Brand Name Expiry Date*

NZ Medical and Scientific Arrow-Etidronate Felo 5 ER Felo 10 ER Fintral AFT AFT AFT Flucloxin Pacific Fludara Fludara Oral FML Flixonase Hayfever & Allergy Diurin 40 Nupentin Pfizer Apo-Gliclazide Minidiab Lycinate Nitrolingual Pumpspray Nitroderm TTS Douglas ABM PSM Colifoam DP Lotn HC ABM Hydroxocobalamin Plaquenil Methopt Buscopan Gastrosoothe Ethics Ibuprofen Ferrum H 2012 2012 2012 2011 2012 2011 2011 2011 2012 31/1/13 2012 31/7/12 2012 2011 2011 2011

Fluconazole Fludarabine phosphate Fluorometholone Fluticasone propionate Furosemide Gabapentin Gentamicin sulphate Gliclazide Glipizide Glyceryl trinitrate

Hydrocortisone

Tab 5 mg & 20 mg Powder Crm 1% Rectal foam 10%, CFC-free (14 applications) Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Tab 200 mg Inj 50 mg per ml, 2 ml

2012 2011 2012 2011 2012 2012 2011 2011 2012 2011

Hydrocortisone acetate Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hypromellose Hysocine N-butylbromide Ibuprofen Iron polymaltose

Sole Subsidised Supply Products – cumulative to July 2010

Generic Name

Isotretinoin Ketoconazole Latanoprost Letrozole Lisinopril Malathion Mask for Spacer Device Mebendazole Mebeverine hydrochloride Mesalazine Metformin hydrochloride Methadone hydrochloride

Presentation

Cap 10 mg & 20 mg Shampoo 2% Eye drops 50 µg per ml Tab 2.5 mg Tab 5 mg, 10 mg & 20 mg Shampoo 1% Device Tab 100 mg Tab 135 mg Enema 1 g per 100 ml Tab immediate-release 500 mg & 850 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 2.5 mg & 10 mg Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 125 mg, 250 mg & 500 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Inj 5 mg per ml, 2 ml Crm 2% Crm 0.1% Oint 0.1% Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab immediate release 10 mg & 20 mg Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml

Brand Name Expiry Date*

Oratane Sebizole Hysite Letara Arrow-Lisinopril A-Lices Foremount Child’s Silicone Mask De-Worm Colofac Pentasa Apotex Biodone Biodone Forte Biodone Extra Forte Methoblastin Methotrexate Ebewe Methotrexate Ebewe Prodopa Medrol Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Multichem m-Mometasone m-Mometasone RA-Morph RA-Morph RA-Morph RA-Morph Sevredol Mayne Mayne 2012 2011 2012 2012 2012 2011 30/9/11 2011 2011 2012 2012 2012

Methotrexate

2012 2011 2011 2012 2011 2011 2012

Methyldopa Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate

Metoclopramide hydrochloride Miconazole nitrate Mometasone furoate Morphine hydrochloride

2011 2011 2012 2012

Morphine sulphate

2012 2011

Sole Subsidised Supply Products – cumulative to July 2010

Generic Name

Naproxen Nevirapine

Presentation

Tab 250 mg Tab 500 mg Oral suspension 10 mg per ml Tab 200 mg

Brand Name Expiry Date*

Noflam 250 Noflam 500 Viramune Suspension Viramune Noriday 28 Primolut N Norpress Nilstat Dr Reddy’s Omeprazole Dr Reddy’s Omeprazole Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Pharmacare Paracare Junior Paracare Double Strength ParaCode Breath-Alert Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax A-Scabies Apo-Pindolol Pizaccord Sandomigran Coloxyl 2012 2012

Norethisterone Nortriptyline hydrochloride Nystatin Omeprazole

Tab 350 µg Tab 5 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml, 24 ml OP Cap 10 mg, 20 mg & 40 mg Inj 40 mg

2012 2011 2011 2011 2011

Oxytocin

Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Low range and Normal range Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Tab 0.25 mg & 1 mg Lotn 5% Tab 5 mg, 10 mg & 15 mg Tab 15 mg, 30 mg & 45 mg Tab 500 µg Oral drops 10%

2012

Pamidronate disodium

2011

Paracetamol

2011

Paracetamol with codeine Peak Flow Meter Pegylated interferon alpha-2A

2012 30/9/11 31/12/12

Pergolide Permethrin Pindolol Pioglitazone Pizotifen Poloxamer

2011 2011 2012 2012 2012 2011

Sole Subsidised Supply Products – cumulative to July 2010

Generic Name

Polyvinyl alcohol Potassium chloride Prednisone Prednisone sodium phosphate Procaine penicillin Promethazine hydrochloride

Presentation

Eye drops 1.4% Eye drops 3% Tab long-acting 600 mg Tab 1 mg, 2.5 mg, 5 mg & 20 mg Oral liq 5 mg per ml Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg

Brand Name Expiry Date*

Vistil Vistil Forte Span-K Apo-Prednisone Redipred Cilicaine Promethazine Winthrop Elixir Allersoothe Accupril Accuretic 10 Accuretic 20 Q 300 ArrowRoxithromycin Asthalin Asthalin Duolin 2012 2012 2012 2012 2011 2012 2011 2012 2011 2012 2011 2011 2011

Quinapril Quinapril with hydroclorothiazide

Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydroclorothiazide 12.5 mg Tab 20 mg with hydroclorothiazide 12.5 mg Tab 300 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Nasal spray, 4% Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Tab 80 mg & 160 mg 230 ml Tab 50 mg & 100 mg Soln 2.3% Tab 10 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 µg Inj 1 mg per ml, 1 ml

Quinine sulphate Roxithromycin Salbutamol Salbutamol with ipratropium bromide Selegiline hydrochloride Simvastatin

Apo-Selegiline Arrow-Simva 10 mg Arrow-Simva 20 mg Arrow-Simva 40 mg Arrow-Simva 80 mg Rex Genotropin Genotropin Mylan Space Chamber Arrow-Sumatriptan Pinetarsol Normison Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot

2012 2011

Sodium cromoglycate Somatropin Sotalol Spacer Device Sumatriptan Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terbinafine Testosterone cypionate Tetracosactrin

2012 31/12/12 2012 30/9/11 2013 2011 2011 2011 2011 2011

Sole Subsidised Supply Products – cumulative to July 2010

Generic Name

Timolol maleate Tranexamic acid Triamcinolone acetonide

Presentation

Tab 10 mg Eye drops 0.25% & 0.5% Tab 500 mg Crm 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP Tab 300 mg Cap 5 mg Cap 300 mg Inj 50 mg per ml, 10 ml Cap 100 mg Oral liq 10 mg per ml Oint BP Cap 137.4 mg (50 mg elemental) Tab 7.5 mg

Brand Name Expiry Date*

Apo-Timol Apo-Timop Cycklokapron Aristocort Aristocort Kenacort-A40 Oracort TMP Navoban Actigall Pacific Retrovir Retrovir PSM Zincaps Apo-Zopiclone 2012 2011 2013 2011

Trimethoprim Tropisetron Ursodeoxycholic acid Vancomycin hydrochloride Zidovudine [AZT] Zinc and castor oil Zinc sulphate Zopiclone July changes in bold

2011 2012 2011 2011 2013 2011 2011 2011

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 July 2010

25 35 POTASSIUM IODATE Tab 268 µg (150 µg elemental) ................................................. 7.55 90 ✔ NeuroKare ✔ Pinorax

DANTHRON WITH POLOXAMER – Only on a prescription Oral liq 25 mg with poloxamer 200 mg per 5 ml ......................... 9.50 300 ml Note: Only for the prevention or treatment of constipation in the terminally ill. MULTIVITAMINS – Special Authority see SA0963 – Retail pharmacy Powder ................................................................................... 72.00 VITAMINS ❋ Tab (BPC cap strength) ........................................................... 10.85 AMLODIPINE ❋ Tab 5 mg ................................................................................ 22.82 ❋ Tab 10 mg .............................................................................. 34.85 TRETINOIN Crm 0.5 mg per g .................................................................... 13.90 a) maximum of 50 g per prescription 200 g OP 1,000 30 30 50 g OP

37 38 54

✔ Paediatric Seravit ✔ MultiADE ✔ Norvasc ✔ Norvasc ✔ ReTrieve

COAL TAR Soln BP – Only in combination ................................................. 12.95 200 ml ✔ Midwest Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod – Plain, refer, page 163 With or without other dermatological galenicals. OESTRADIOL – See prescribing guideline ❋ TDDS 50 µg per day .................................................................. 4.12 8 (13.18) Estradot 50 mcg a) Higher subsidy of $13.18 per 8 patch with Special Authority see SA1018 on the preceding page b) No more than 2 patch per week c) Only on a prescription CLOMIPHENE CITRATE Tab 50 mg ............................................................................. 29.84 10 ✔ Serophene

82 95 113 158

LOPINAVIR WITH RITONAVIR – Special Authority see SA1021 – Hospital pharmacy [HP1] Tab 100 mg with ritonavir 25 mg .......................................... 183.75 60 ✔ Kaletra FLUOXETINE HYDROCHLORIDE ❋ Cap 20 mg ................................................................................ 2.70 FLUMETASONE PIVALATE Ear drops 0.02% with clioquinol 1% ........................................... 4.46 GLYCEROL ❋ Liquid – Only in combination.................................................... 17.86 Only in extemporaneously compounded oral liquid preparations. 84 ✔ Fluox

7.5 ml OP ✔ Locacorten-Vioform ED's 2,000 ml ✔ healthE

167

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 July 2010 (continued)

172 PROTEIN SUPPLEMENT – Special Authority see SA0582 – Hospital pharmacy [HP3] Powder ..................................................................................... 8.95 227 g OP ✔ Resource Beneprotein

185

AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0962 – Retail pharmacy See prescribing guideline Powder ................................................................................... 23.38 100 g OP ✔ Metabolic Mineral Mixture

Effective 1 June 2010

49 ENALAPRIL ❋ Tab 5 mg ................................................................................. 1.98 ❋ Tab 10 mg ............................................................................... 2.44 ❋ Tab 20 mg ............................................................................... 3.24 NANDROLONE DECANOATE – Retail pharmacy-Specialist Inj 50 mg per ml, 1 ml ............................................................ 21.16 TRAMADOL HYDROCHLORIDE Cap 50 mg ................................................................................ 6.95 CYTARABINE Inj 500 mg – PCT – Retail pharmacy-Specialist ....................... 18.15 Inj 1 g – PCT – Retail pharmacy-Specialist .............................. 37.00 Inj 2 g – PCT only – Specialist ................................................. 31.00 IRINOTECAN – PCT only – Specialist – Special Authority see SA0878 Inj 20 mg per ml, 2 ml ............................................................ 41.00 Inj 20 mg per ml, 5 ml .......................................................... 100.00 MITOMYCIN C – PCT only – Specialist Inj 5 mg ................................................................................. 72.75 90 90 90 1 ✔ Arrow-Enalapril ✔ Arrow-Enalapril ✔ Arrow-Enalapril ✔ Deca-Durabolin Orgaject S29 ✔ Arrow-Tramadol ✔ Pfizer ✔ Pfizer ✔ Pfizer ✔ Irinotecan-Rex ✔ Irinotecan-Rex ✔ Arrow S29

109 138

100 1 1 1 1 1 1

139

142

Effective 28 May 2010

52 ATENOLOL ❋ Tab 50 mg ............................................................................. 12.36 ❋ Tab 100 mg ........................................................................... 21.46 1,000 1,000 ✔ Atenolol Tablet USP ✔ Atenolol Tablet USP

Effective 5 May 2010

100 DICLOFENAC SODIUM ❋ Tab EC 25 mg ........................................................................... 1.63 ❋ Tab EC 50 mg ........................................................................... 2.13 50 50 ✔ Diclofenac Sandoz ✔ Diclofenac Sandoz

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 May 2010

55 77 109 138 BENDROFLUAZIDE ❋ Tab 2.5 mg – Up to 150 tab available on a PSO ......................... 7.58 May be supplied on a PSO for reasons other than emergency. ❋ Tab 5 mg ............................................................................... 11.75 TESTOSTERONE UNDECANOATE – Retail pharmacy–Specialist Cap 40 mg .............................................................................. 79.92 LIGNOCAINE Gel 2%, 10 ml urethral syringe ................................................. 43.26 FLUOROURACIL SODIUM Inj 50 mg per ml, 10 ml – PCT only – Specialist ....................... 24.75 500 500 100 10 5 ✔ Arrow Bendrofluazide ✔ Arrow Bendrofluazide ✔ Arrow-Testosterone ✔ Pfizer ✔ Fluorouracil Ebewe

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 July 2010

73 77 CLOTRIMAZOLE ❋ Vaginal crm 1% with applicator(s) ............................................. 1.30 35 g OP ✔ Clomazol

Hormone Replacement Therapy – Systemic ➽ SA10180312 Special Authority for Alternate Subsidy Initial application only from any relevant practitioner an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease – where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient’s record; or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or 3 hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens; or 4 Somatropin co-therapy – patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group. Renewal only from a relevant practitioner an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy. CLOMIPHENE CITRATE – Retail pharmacy-Specialist Only a prescription for a female patient. Tab 50 mg ................................................................................ 2.50 29.84 DAPSONE – No patient co-payment payable Tab 25 mg .............................................................................. 95.00 Tab 100 mg .......................................................................... 110.00

5 10

✔ Phenate ✔ Serophene

100 100

✔ Dapsone S29 ✔ Dapsone S29

Antiretrovirals ➽ SA10210779 Special Authority for Subsidy Initial application — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or 2.3.2.3 Viral load counts > 100000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2010 (continued)

continued... Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals. Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive. Renewal – (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals. Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Prevention of maternal foetal transmission; or 2 Treatment of the newborn for up to eight weeks. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals. Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated. Renewal – (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. Initial application - (Post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both: 1 Treatment course to be initiated within 72 hours post exposure; and 2 Either: 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person. Renewal - (Second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both: 1 Treatment course to be initiated within 72 hours post exposure; and 2 Either: 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2010 (continued)

99 INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available between 1 March and 30 June until vaccine supplies are exhausted each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin. c) people under 65 years of age who are: i) pregnant; or ii) morbidly obsese d) children aged over 6 months and under 5 years who are from high deprivation backgrounds The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease, B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj ............................................................................................. 9.00 1 ✔ Fluvax 90.00 10 ✔ Influvac ✔ Vaxigrip DOMPERIDONE – Additional subsidy by Special Authority see SA0938 below – Retail pharmacy ❋ Tab 10 mg ................................................................................ 7.99 100 ✔ Motilium ➽ SA0938 Special Authority for Manufacturers Price Initial application from any relevant practitioner. Approvals valid for 6 months where the patient is terminally ill and requires control of nausea and vomiting. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

120

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2010 (continued)

122 TOLCAPONE – Retail pharmacy-Specialist prescription Specialist must be a neurologist, geriatrician or general physician. ▲ Tab 100 mg .......................................................................... 128.75

100

✔ Tasmar

146

OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA10160563 – Hospital pharmacy [HP3] Inj 50 µg per ml, 1 ml .............................................................. 25.65 5 ✔ Hospira 43.50 ✔ Sandostatin Inj 100 µg per ml, 1 ml ............................................................ 48.50 5 ✔ Hospira 81.00 ✔ Sandostatin Inj 500 µg per ml, 1 ml .......................................................... 175.00 5 ✔ Hospira 399.00 ✔ Sandostatin Inj LAR 10 mg prefilled syringe ........................................... 1,772.50 1 ✔ Sandostatin LAR Inj LAR 20 mg prefilled syringe ........................................... 2,358.75 1 ✔ Sandostatin LAR Inj LAR 30 mg prefilled syringe ........................................... 2,951.25 1 ✔ Sandostatin LAR ➽ SA10160563 Special Authority for Subsidy Initial application – (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria: All of the following: 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and 3 Octreotide to be given up to a maximum dose of 1,500 μg daily for up to 4 weeks. Renewal – (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: indications marked with * are Unapproved Indications. Initial application – (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 The patient has acromegaly; and 2 Any of the following 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy. Renewal – (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1. IGF1 levels have decreased since starting octreotide; and 2. The treatment remains appropriate and the patient is benefiting from treatment. Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks. Initial application – (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2010 (continued)

continued... 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 21 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 32 Both: 32.1 Gastrinoma; and 32.2 Either: 32.2.1 Patient has failed surgery; or 32.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 43 Both: 43.1 Insulinomas; and 43.2 Surgery is contraindicated or has failed; or 54 For pre-operative control of hypoglycaemia and for maintenance therapy; or 65 Both: 65.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 65.2 Disabling symptoms not controlled by maximal medical therapy. Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item. Renewal – (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. 149 TRASTUZUMAB – PCT only – Specialist – Special Authority see SA10170885 Inj 150 mg vial .............................................................................1,350.00 1 Inj 440 mg vial .............................................................................3,875.00 1 Inj 1 mg for ECP .................................................................................9.36 1 mg ✔ Herceptin ✔ Herceptin ✔ Baxter

➽ SA10170885 Special Authority for Subsidy Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has metastatic breast cancer expressing HER-2 IHC 3+ or FISH+. Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic breast cancer; and 2 The cancer has not progressed. Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 15 months for applications meeting the following criteria: All of the following: 1 The patient has early breast cancer expressing HER 2 IHC 3+ or FISH + ISH + (including FISH or other current technology); and 2 Maximum cumulative dose of 20106 mg/kg (9 weeks 12 months’ treatment)*; and 3 Any of the following: 3.1 9 weeks’ concurrent treatment with adjuvant chemotherapy is planned; or 3.2 12 months’ concurrent treatment with adjuvant chemotherapy is planned; or 3.3 12 months’ sequential treatment following adjuvant chemotherapy is planned; or 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned. 3 Trastuzumab is to be given concurrently with adjuvant taxane chemotherapy*; and 4 Trastuzumab is not to be given concurrently with anthracycline chemotherapy. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2010 (continued)

continued... Notes: indications marked with * are Unapproved Indications. It is recommended that for early breast cancer trastuzumab be administered concurrently with docetaxel prior to anthracyclines as per the FinHer regimen (Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20). Note: For patients with previous Special Authority approvals for a maximum cumulative dose of 20 mg/kg (9 weeks treatment) granted after 1 April 2009 the approval period has been extended to allow claims for a maximum cumulative dose of 106 mg/kg (12 months treatment)

Effective 1 June 2010

33 PANCREATIC ENZYME Cap 8,000 USP u lipase, 30,000 USP u amylase, 30,000 USP u protease – Retail pharmacy-Specialist ........... 85.00 Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease – Retail pharmacy-Specialist................... 34.93 Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease – Retail pharmacy-Specialist................ 94.38 Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease – Retail pharmacy-Specialist................ 94.40 FERROUS SULPHATE ❋‡ Oral liq 30 mg per 1 ml 150 mg per 5 ml (6 mg elemental per 1 ml 30 mg elemental per 1 ml) .............. 10.30 MALATHION Liq 0.5% ................................................................................... 4.99 250 100 100 100 ✔ Cotazym ECS ✔ Creon 10000 ✔ Creon Forte ✔ Panzytrat

500 ml

✔ Ferodan

65 71

200 ml OP ✔ Derbac-M

COMBINED ORAL CONTRACEPTIVES ➽ SA0500 Special Authority for Alternate Subsidy Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon, and Marvelon, Minulet and Femodene. The additional subsidy will fund Mercilon, and Marvelon, Minulet and Femodene up to the manufacturer’s price for each of these products as identified on the Schedule at 1 November 1999. Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either: • on a Social Welfare benefit; or • have an income no greater than the benefit. The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2010 (continued)

72 PROGESTOGEN-ONLY CONTRACEPTIVES ➽ SA0500 Special Authority for Alternate Subsidy Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon, and Marvelon, Minulet and Femodene. The additional subsidy will fund Mercilon, and Marvelon, Minulet and Femodene up to the manufacturer’s price for each of these products as identified on the Schedule at 1 November 1999. Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either: • on a Social Welfare benefit; or • have an income no greater than the benefit. The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED 107 ALENDRONATE SODIUM – Special Authority see SA0990 – Retail pharmacy Tab 70 mg ............................................................................. 35.91 4 ✔ Fosamax

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA0990 – Retail pharmacy Tab 70 mg with cholecalciferol 5,600 iu .................................. 35.91 4 ✔ Fosamax Plus Tab 70 mg with cholecalciferol 2,800 iu .................................. 35.91 4 ✔ Fosamax Plus ➽ SA0990 Special Authority for Subsidy Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo) which incorporates BMD measurements (see Note). Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and 2 Either: continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2010 (continued)

continued... 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically. Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents). Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the ’Underlying cause osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo) which incorporates BMD measurements (see Note). Notes: a) BMD (including BMD used to derive T-Score) must be derived measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates. c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

135

NALTREXONE HYDROCHLORIDE – Special Authority see SA0909 – Retail pharmacy Tab 50 mg ........................................................................... 180.00 30 ✔ ReVia ➽ SA0909 Special Authority for Subsidy Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the 21 District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard. Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: continued... ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2010 (continued)

continued... 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maintenance therapy. The patient may not have had more than 1 prior approval in the last 12 months. 138 CYTARABINE Inj 500 mg 100 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist ................................................... 18.15 95.36 Inj 1 g 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist .................................................. 37.00 42.65 Inj 2 g 100 mg per ml, 20 ml – PCT only – Specialist ............... 31.00 34.47 CYTARABINE Inj 1 mg for ECP – PCT only – Specialist ................................... 0.30

1 5 1 1 1 1 10 1 mg

✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne ✔ Baxter

138

Effective 1 May 2010

34 DOCUSATE SODIUM – Only on a prescription ❋ Tab Cap 50 mg ......................................................................... 3.95 ❋ Tab Cap 120 mg ....................................................................... 5.49 CALCIUM CARBONATE ❋ Tab eff 1.75 g (1 g elemental) .................................................. 6.54 CALCIUM CARBONATE ❋ Tab 1.25 g (500 mg elemental) ................................................ 9.18 ❋ Tab 1.5 g (600 mg elemental) ................................................ 10.33 SODIUM FLUORIDE Tab 1.1 mg (0.5 mg elemental) ................................................ 4.00 FERROUS FUMARATE Tab 200 mg (65 mg elemental) ................................................ 4.35 FERROUS FUMARATE WITH FOLIC ACID Tab 310 mg (100 mg elemental) with folic acid 350 µg ............ 4.75 FERROUS GLUCONATE WITH ASCORBIC ACID ❋ Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg ....... 12.04 FERROUS SULPHATE ❋ Tab long-acting 325 mg (105 mg elemental) ............................ 5.06 (15.58) ❋‡ Oral liq 150 mg per 5 ml (30 mg elemental per 1 ml) ........... 10.30 100 100 30 250 250 100 100 60 500 ✔ Laxofast 50 ✔ Laxofast 120 ✔ Calsource ✔ Calci-Tab 500 ✔ Calci-Tab 600 ✔ PSM ✔ Ferro-tab ✔ Ferro-F-Tabs ✔ Healtheries Iron with Vitamin C

38 38

38 38 38 38

150 500 ml Ferro-Gradumet ✔ Ferodan

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2010 (continued)

39 FERROUS SULPHATE WITH FOLIC ACID ❋ Tab long-acting 325 mg (105 mg elemental) with folic acid 350 µg .................................................................. 1.80 (3.73) MAGNESIUM SULPHATE Inj 49.3%, 5 ml ....................................................................... 26.60 ZINC SULPHATE ❋ Cap 220 137.4 mg (50 mg elemental) ................................... 10.00

30 Ferrograd-Folic 10 100 ✔ Mayne ✔ Zincaps

39 39 138

GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1012 0877 Inj 1 g ................................................................................... 245.00 1 ✔ Gemcitabine Ebewe 349.20 ✔ Gemzar Inj 200 mg .............................................................................. 49.00 1 ✔ Gemcitabine Ebewe 78.00 ✔ Gemzar Inj 1 mg for ECP ....................................................................... 0.26 1 mg ✔ Baxter ➽ SA1012 0877 Special Authority for Subsidy Initial application - (Hodgkin’s disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following 1 The patient has Hodgkin’s disease*; and 2 Either 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or 2.2 Disease has relapsed following transplant; or 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant. 3 Gemcitabine to be given for a maximum of 6 treatment cycles. Initial application - (T-cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following 1 The patient has T-cell lymphoma*; and 2 Gemcitabine to be given for a maximum of 6 treatment cycles. Initial application - (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or 2 The patient has advanced malignant mesothelioma*; or 3 The patient has advanced pancreatic carcinoma; or 4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or 5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal - (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Note: Indications marked with a * are Unapproved Indications.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2010 (continued)

143 VINORELBINE – PCT only – Specialist – Special Authority see SA1013 0901 Inj 10 mg per ml, 1 ml ............................................................ 24.00 1 42.00 Inj 10 mg per ml, 5 ml ........................................................... 120.00 1 210.00 Inj 1 mg for ECP ........................................................................ 2.71 1 mg ✔ Navelbine ✔ Vinorelbine Ebewe ✔ Navelbine ✔ Vinorelbine Ebewe ✔ Baxter

➽ SA1013 0901 Special Authority for Subsidy Initial application - (Hodgkin’s disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following 1 The patient has Hodgkin’s disease*; and 2 Either 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or 2.2 Disease has relapsed following transplant; or 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant. 3 Vinorelbine to be given for a maximum of 6 treatment cycles. Initial application - (T-cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following 1 The patient has T-cell lymphoma*; and 2 Vinorelbine to be given for a maximum of 6 treatment cycles. Initial application – (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has metastatic breast cancer; or 2 The patient has non-small cell lung cancer (stage IIIa, or above); or 3 All of the following: 3.1 The patient has stage IB-IIIA non-small cell lung cancer; and 3.2 Vinorelbine is to be given as adjuvant treatment in combination with cisplatin; and 3.3 The patient has good performance status (WHO/ECOG grade 0-1). Renewal – (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Note: Indications marked with a * are Unapproved Indications.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 July 2010

28 PANTOPRAZOLE ( subsidy) ❋ Tab 20 mg ................................................................................ 1.23 ❋ Tab 40 mg ................................................................................ 1.54 35 41 45 BISACODYL – Only on a prescription ( subsidy) ❋ Tab 5 mg .................................................................................. 4.99 ASPIRIN ( subsidy) ❋ Tab 100 mg ............................................................................ 14.00 DEXTROSE WITH ELECTROLYTES ( subsidy) Soln with electrolytes................................................................. 6.60 6.75 53 METOPROLOL SUCCINATE ( subsidy) ❋ Tab long-acting 23.75 mg ......................................................... 2.18 ❋ Tab long-acting 47.5 mg ........................................................... 2.74 ❋ Tab long-acting 95 mg .............................................................. 4.71 ❋ Tab long-acting 190 mg ............................................................ 8.51 55 BENDROFLUAZIDE ( subsidy) ❋ Tab 2.5 mg – Up to 150 tab available on a PSO ......................... 7.58 (13.50) May be supplied on a PSO for reasons other than emergency. ❋ Tab 5 mg ............................................................................... 11.75 (21.50) SPIRONOLACTONE ( subsidy) ❋ Tab 25 mg ................................................................................ 4.60 ❋ Tab 100 mg ............................................................................ 15.15 FUSIDIC ACID ( subsidy) Crm 2% ..................................................................................... 3.25 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination Oint 2% ..................................................................................... 3.25 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination 28 28 ✔ Dr Reddy’s Pantoprazole ✔ Dr Reddy’s Pantoprazole ✔ Lax-Tabs ✔ Ethics Aspirin EC

200 990

1,000 ml OP ✔ Pedialyte Bubblegum ✔ Pedialyte - Fruit ✔ Pedialyte - Plain 30 30 30 30 ✔ Betaloc CR ✔ Metoprolol - AFT CR ✔ Betaloc CR ✔ Metoprolol - AFT CR ✔ Betaloc CR ✔ Metoprolol - AFT CR ✔ Betaloc CR ✔ Metoprolol - AFT CR

500 Neo-Naclex 500 Neo-Naclex 100 100 15 g OP ✔ Spirotone ✔ Spirotone ✔ Foban

15 g OP

✔ Foban

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price - effective 1 July 2010 (continued)

63 64 66 HYDROCORTISONE WITH MICONAZOLE – Only on a prescription ( subsidy) ❋ Crm 1% with miconazole nitrate 2% ........................................... 2.10 15 g OP CETOMACROGOL ( subsidy) ❋ Crm BP ..................................................................................... 3.15 500 g ✔ Micreme H ✔ PSM

COAL TAR ( subsidy) Soln BP – Only in combination ................................................. 32.37 500 ml ✔ PSM Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod – Plain, refer, page 163 With or without other dermatological galenicals. CLOTRIMAZOLE ( subsidy) ❋ Vaginal crm 1% with applicators ................................................ 1.30 ❋ Vaginal crm 2% with applicators ................................................ 2.50 TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist ( subsidy) Cap 40 mg .............................................................................. 47.95 (60.71) CABERGOLINE ( subsidy) Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA0175 ................. 16.50 66.00 CEFACLOR MONOHYDRATE ( subsidy) Grans for oral liq 125 mg per 5 ml ............................................. 3.53 PHENOXYMETHYLPENICILLIN (PENICILLIN V) ( subsidy) Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO ............................................................................... 1.78 IBUPROFEN ( subsidy) ❋‡ Oral liq 100 mg per 5 ml.......................................................... 2.69 ASPIRIN ( subsidy) ❋ Tab EC 300 mg ......................................................................... 2.00 (8.10) ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ......... 2.00 35 g OP 20 g OP 60 ✔ Clomazol ✔ Clomazol ✔ Andriol Testocaps Panteston

2 8 100 ml

✔ Arrow-Cabergoline ✔ Arrow-Cabergoline ✔ Ranbaxy-Cefaclor

84 87

100 ml 200 ml 100 100

✔ AFT ✔ Fenpaed

100 109

Aspec 300 ✔ Ethics Aspirin

113

FLUOXETINE HYDROCHLORIDE ( subsidy) ❋ Tab dispersible 20 mg, scored – Subsidy by endorsement ......... 2.50 30 ✔ Fluox Subsidised by endorsement 1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or 2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses. ❋ Cap 20 mg ............................................................................... 2.89 90 ✔ Fluox PAROXETINE HYDROCHLORIDE ( subsidy) Tab 20 mg ............................................................................... 2.38 30 ✔ Loxamine

113

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price - effective 1 July 2010 (continued)

117 PHENYTOIN SODIUM ( subsidy) ❋ Tab 50 mg .............................................................................. 42.09 ❋ Cap 30 mg .............................................................................. 19.13 ❋ Cap 100 mg ............................................................................ 17.21 ❋‡ Oral liq 30 mg per 5 ml.......................................................... 19.16 DOMPERIDONE ( subsidy) ❋ Tab 10 mg ................................................................................ 7.99 ROPINIROLE HYDROCHLORIDE ( subsidy) ▲ Tab 0.25 mg ............................................................................. 6.20 ▲ Tab 1 mg ................................................................................ 15.95 ▲ Tab 2 mg ................................................................................ 24.95 ▲ Tab 5 mg ................................................................................ 38.00 CISPLATIN – PCT only – Specialist ( subsidy) Inj 1 mg for ECP ........................................................................ 0.27 200 200 200 500 ml 100 84 84 84 84 1 mg ✔ Dilantin Infatab ✔ Dilantin ✔ Dilantin ✔ Dilantin ✔ Motilium ✔ Ropin ✔ Ropin ✔ Ropin ✔ Ropin ✔ Baxter

120 122

136 138

GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority SA0877 ( subsidy) Inj 1 g ..................................................................................... 62.50 1 ✔ Gemcitabine Ebewe Inj 200 mg .............................................................................. 12.50 1 ✔ Gemcitabine Ebewe Inj 1 mg for ECP ........................................................................ 0.07 1 mg ✔ Baxter DOCETAXEL – PCT only – Specialist – Special Authority see SA0880 ( subsidy) Inj 1 mg for ECP ..................................................................... 17.55 1 mg MITOZANTRONE – PCT only – Specialist ( subsidy) Inj 2 mg per ml, 10 ml ........................................................... 100.00 Inj 1 mg for ECP ........................................................................ 5.65 LORATADINE ( subsidy) ❋ Tab 10 mg ................................................................................ 2.09 ❋ Oral liq 1 mg per ml ................................................................... 3.10 1 1 mg 100 100 ml 150 ml 2,000 ml ✔ Baxter ✔ Mitozantrone Ebewe ✔ Baxter ✔ Loraclear Hayfever Relief ✔ Lorapaed ✔ Salapin ✔ PSM

140 142

152

154 167

SALBUTAMOL ( subsidy) ‡Oral liq 2 mg per 5 ml .................................................................. 1.99 GLYCEROL ( subsidy) ❋ Liquid – Only in combination.................................................... 17.86 Only in extemporaneously compounded oral liquid preparations.

172

ORAL SUPPLEMENT 1KCAL/ML – Special Authority – Hospital pharmacy [HP3] ( subsidy) Powder (chocolate) ................................................................. 10.22 900 g OP ✔ Sustagen Hospital Formula Powder (vanilla) ...................................................................... 10.22 900 g OP ✔ Sustagen Hospital Formula ORAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital pharmacy [HP3] ( price) Liquid (vanilla) .......................................................................... 1.78 237 ml OP (2.10) Resource Diabetic

173

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price - effective 1 July 2010 (continued)

176 RENAL ORAL FEED 2KCAL/ML – Special Authority see SA0587 – Hospital pharmacy [HP3] ( price) Liquid ........................................................................................ 2.88 237 ml OP (3.31) NovaSource Renal ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA0592 – Hospital pharmacy [HP3] ( subsidy) Powder (unflavoured) ................................................................ 4.50 80.4 g OP ✔ Vivonex TEN

177

Effective 1 June 2010

34 DOCUSATE SODIUM – Only on a prescription ( subsidy) ❋ Tab 50 mg ............................................................................... 3.95 (4.89) ❋ Tab 120 mg .............................................................................. 5.49 (6.73) RISPERIDONE ( subsidy) Tab 0.5 mg ............................................................................... 1.17 3.51 Tab 1 mg .................................................................................. 6.00 Tab 2 mg ................................................................................ 11.00 Tab 3 mg ................................................................................ 15.00 Tab 4 mg ................................................................................ 20.00 100 Coloxyl 100 Coloxyl 20 60 60 60 60 60 ✔ Ridal ✔ Ridal ✔ Ridal ✔ Ridal ✔ Ridal ✔ Ridal

125

138

CYTARABINE Inj 100 mg – PCT – Retail pharmacy-Specialist ( subsidy) ..... 76.00 5 ✔ Pfizer Inj 1 mg for ECP – PCT only – Specialist ( subsidy) ................. 0.30 10 mg ✔ Baxter Note - Baxter inj 1 mg for ECP subsidy and price increase is pro rated to the new 10 mg pack size. VINCRISTINE SULPHATE Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist ( subsidy) .............................. 108.00 Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ( subsidy) .............................. 116.00 Inj 1 mg for ECP – PCT only – Specialist ( subsidy) ............... 15.77

143

5 5 1 mg

✔ Hospira ✔ Hospira ✔ Baxter

156

BECLOMETHASONE DIPROPIONATE ( price) Metered aqueous nasal spray, 50 µg per dose ........................... 2.35 200 dose OP (4.00) Metered aqueous nasal spray, 100 µg per dose ......................... 2.46 200 dose OP (4.81)

Alanase Alanase

Effective 1 May 2010

61 CROTAMITON ( subsidy) a) Only on a prescription b) Not in combination Crm 10% .................................................................................. 3.79 (4.45)

20 g OP Eurax

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price - effective 1 May 2010 (continued)

63 CHLORHEXIDINE GLUCONATE – Subsidy by endorsement ( subsidy) a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ❋ Handrub 1% with ethanol 70% .................................................. 4.60 500 ml (5.40) PREGNANCY TESTS - HCG URINE ( subsidy) a) Up to 200 test available on a PSO b) Only on a PSO Cassette ................................................................................. 14.25

Orion

25 test OP ✔ MDS Quick Card

LAMIVUDINE – Special Authority see SA0779 – Hospital pharmacy [HP1] ( subsidy) Tab 150 mg ......................................................................... 153.60 60 ✔ 3TC Oral liq 10 mg per ml .............................................................. 50.00 240 ml OP ✔ 3TC CISPLATIN – PCT only – Specialist ( subsidy) Inj 1 mg per ml, 50 ml ............................................................ 15.00 Inj 1 mg per ml, 100 ml .......................................................... 21.00 MEGESTROL ACETATE – Retail pharmacy-Specialist ( subsidy) Tab 160 mg ........................................................................... 57.92 (74.25) 1 1 30 Megace ✔ Cisplatin Ebewe ✔ Cisplatin Ebewe

136

146

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 July 2010

35 108 CHLORHEXIDINE GLUCONATE Mouthwash 0.2% ..................................................................... 3.06 PROBENECID ❋ Tab 500 mg ........................................................................... 55.00 200 ml OP ✔ Rivacol Orion 100 ✔ Probenecid-AFT AFT

Effective 1 June 2010

76 DEXAMETHASONE SODIUM PHOSPHATE ❋ Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 21.50 ❋ Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO .............. 31.00 CYTARABINE Inj 100 mg – PCT – Retail pharmacy-Specialist. ...................... 76.00 VINCRISTINE SULPHATE Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist ..... 108.00 Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ..... 116.00 5 5 5 5 5 ✔ Hospira Mayne ✔ Hospira Mayne ✔ Pfizer Pharmacia ✔ Hospira Mayne ✔ Hospira Mayne

138 143

Changes to Sole Subsidised Supply

Effective 1 July 2010

For the list of new Sole Subsidised Supply products effective 1 July 2010 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 14-20.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 July 2010

36 HYDROXOCOBALAMIN ❋ Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO ................ 6.15 (10.84) SILVER SULPHADIAZINE Crm 1% with chlorhexidine digluconate 0.2% .......................... 15.04 a) Up to 500 g available on a PSO b) Not in combination HYDROCORTISONE BUTYRATE Milky emul 0.1% ....................................................................... 5.00 DITHRANOL Crm 1% ................................................................................... 27.50 SOMATROPIN – Special Authority see SA0755 ❋ Inj 5 mg ............................................................................... 300.00 ❋ Inj 10 mg ............................................................................. 600.00 ❋ Inj 15 mg ............................................................................. 900.00 138 FLUDARABINE PHOSPHATE – PCT only – Specialist Tab 10 mg ........................................................................... 650.25 Note – Fludara Oral tab 10 mg, 20 tab pack size remains listed. LETROZOLE Tab 2.5 mg ............................................................................ 26.55 (146.46) PROMETHAZINE HYDROCHLORIDE ❋‡ Oral liq 5 mg per 5 ml ............................................................. 3.10 (8.51) 3 Neo-B12 100 g OP ✔ Silvazine

62 67 81

30 ml OP 50 g OP 1 1 1

✔ Locoid Crelo ✔ Micanol ✔ Norditropin SimpleXx 5mg ✔ Norditropin SimpleXx 10mg ✔ Norditropin SimpleXx 15mg ✔ Fludara

146

30 Femara 100 ml Phenergan

152

Effective 1 June 2010

27 28 ATROPINE SULPHATE ❋ Inj 1200 µg, 1 ml – Up to 5 inj available on a PSO.................... 32.00 OMEPRAZOLE ❋ Cap 10 mg ............................................................................... 2.00 ❋ Cap 40 mg .............................................................................. 3.35 50 28 28 ✔ AstraZeneca ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole

Note – Dr Reddy’s Omeprazole cap 10 mg and 40 mg, 30 cap pack, remain listed. 44 POTASSIUM CHLORIDE ❋ Inj 150 mg per ml, 10 ml ......................................................... 26.00 Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. 50 ✔ AstraZeneca

▲

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 June 2010 (continued)

52 ATENOLOL ❋ Tab 50 mg ................................................................................ 0.39 PINDOLOL ❋ Tab 5 mg .................................................................................. 4.50 ❋ Tab 10 mg ................................................................................ 8.35 ❋ Tab 15 mg .............................................................................. 12.00 30 100 100 100 ✔ Noten S29 ✔ Pindol ✔ Pindol ✔ Pindol

ETHINYLOESTRADIOL WITH GESTODENE ❋ Tab 30 µg with gestodene 75 µg and 7 inert tab ........................ 6.62 84 (16.50) a) Higher subsidy of $14.49 per 84 tab with Special Authority see SA0500 above b) Up to 84 tab available on a PSO FLUCLOXACILLIN SODIUM Cap 250 mg – Up to 30 cap available on a PSO ....................... 18.50 Cap 500 mg ............................................................................ 57.90 DICLOFENAC SODIUM ❋ Tab long-acting 75 mg ............................................................ 19.60 CLOMIPRAMINE HYDROCHLORIDE Tab 10 mg .............................................................................. 10.00 PARACETAMOL WITH CODEINE ❋ Tab paracetamol 500 mg with codeine phosphate 8 mg ............ 2.45 (3.24) BROMOCRIPTINE MESYLATE ❋ Tab 2.5 mg ............................................................................ 32.08 BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu .......................................................................... 680.00 250 500 100 100 100

Femodene 28

✔ Staphlex ✔ Staphlex ✔ Voltaren SR ✔ Clopress

100 112 112

Codalgin 100 ✔ AlphaBromocriptine ✔ Blenoxane

121

140

Effective 1 May 2010

30 METFORMIN HYDROCHLORIDE ❋ Tab immediate-release 500 mg ................................................. 8.09 ❋ Tab immediate-release 850 mg ................................................. 6.67 CALCITRIOL ❋ Cap 0.25 µg ........................................................................... 10.10 ❋ Cap 0.5 µg ............................................................................. 18.73 PERMETHRIN Crm 5% .................................................................................... 3.65 (4.20) 500 250 100 100 30 g OP Lyderm ✔ Arrow-Metformin ✔ Arrow-Metformin ✔ Calcitriol-AFT ✔ Calcitriol-AFT

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 May 2010 (continued)

65 WOOL FAT WITH MINERAL OIL – Only on a prescription ❋ Lotn hydrous 3% with mineral oil .............................................. 1.12 (5.00) 2.10 (9.38) 200 ml OP Alpha-Keri Lotion 375 ml OP Alpha-Keri Lotion

SUNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly. Lotn ......................................................................................... 3.19 125 ml OP (8.82) Aquasun Sensitive SPF 30+ AMOXYCILLIN Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO ............................................................................... 1.27 LAMOTRIGINE ▲ Tab dispersible 200 mg ........................................................ 101.80 SUMATRIPTAN Tab 50 mg ............................................................................... 1.55 (12.00) (22.00) Tab 100 mg ............................................................................. 1.55 (12.00) (22.00) TENIPOSIDE – PCT only – Specialist Inj 10 mg per ml, 5 ml .......................................................... 845.11 Inj 50 mg for ECP ................................................................... 84.51 DEXTROCHLORPHENIRAMINE MALEATE ❋ Tab 2 mg ................................................................................. 1.26 (5.60) 2.52 (9.99)

100 ml 56 4

✔ Ranbaxy Amoxicillin ✔ Arrow-Lamotrigine

117 119

Sumagran Imigran 2 Sumagran Imigran 10 ✔ Vumon 50 mg OP ✔ Baxter 25 Polaramine 50 Polaramine

143

151

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 August 2010

61 CROTAMITON a) Only on a prescription b) Not in combination Crm 10% .................................................................................. 3.79 (4.45)

20 g OP Eurax

CHLORHEXIDINE GLUCONATE – Subsidy by endorsement a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ❋ Handrub 1% with ethanol 70% .................................................. 4.60 500 ml (5.40) PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette ................................................................................. 14.25 DICLOFENAC SODIUM ❋ Tab long-acting 75 mg ............................................................. 3.10 Note – Diclax SR tab long-acting 75 mg, 500 tab pack, remains listed. DEXTROPROPOXYPHENE WITH PARACETAMOL Tab napsylate 50 mg with paracetamol 325 mg ...................... 14.50 (22.50) Cap hydrochloride 32.5 mg with paracetamol 325 mg ............... 3.98 (4.90) 19.91 (33.14) MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg ........................................................................... 57.92 (74.25)

Orion

25 test OP ✔ MDS Quick Card 30 ✔ Diclax SR

100

110

500 Paradex 100 Capadex 500 Capadex

146

30 Megace

Effective 1 September 2010

34 DOCUSATE SODIUM – Only on a prescription ❋ Tab 50 mg ................................................................................ 3.95 (4.89) ❋ Tab 120 mg .............................................................................. 5.49 (6.73) 100 Coloxyl 100 Coloxyl

Effective 1 October 2010

55 BENDROFLUAZIDE ❋ Tab 2.5 mg – Up to 150 tab available on a PSO ......................... 7.58 (13.50) May be supplied on a PSO for reasons other than emergency. ❋ Tab 5 mg ............................................................................... 11.75 (21.50)

S29

500 Neo-Naclex 500 Neo-Naclex

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 October 2010 (continued)

77 TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist Cap 40 mg ............................................................................. 47.95 (60.71) 60 ✔ Andriol Testocaps Panteston

Effective 1 November 2010

55 62 FUROSEMIDE ❋ Tab 500 mg ........................................................................... 12.00 HYDROCORTISONE ❋ Crm 1% – Only on a prescription .............................................. 2.44 ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab ethinyloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinyloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab – Up to 84 tab available on a PSO................ 6.62 DYDROGESTERONE Tab 10 mg ............................................................................. 27.50 (29.90) Note – Duphaston tab 10 mg, 28 tab pack remains listed. DANAZOL – Retail pharmacy-Specialist Cap 200 mg ........................................................................... 29.35 DICLOFENAC SODIUM ❋ Tab EC 25 mg ........................................................................... 1.63 ❋ Tab EC 50 mg ........................................................................... 2.13 ❋ Tab long-acting 75 mg ........................................................... 22.78 ❋ Tab long-acting 100 mg ......................................................... 34.32 Note – Diclax SR tab long-acting 75 mg, 500 tab pack, remains listed. CLOMIPRAMINE HYDROCHLORIDE Tab 25 mg ............................................................................. 26.00 100 100 g ✔ Diurin 500 ✔ Lemnis Fatty Cream HC

84 50

✔ Trifeme

Duphaston

83 100

30 50 50 500 500

✔ D-Zol ✔ Diclohexal ✔ Diclohexal ✔ Apo-Diclo SR ✔ Apo-Diclo SR

112 113

500

✔ Clopress

MOCLOBEMIDE Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide. Tab 150 mg ............................................................................. 8.31 60 ✔ GenRx Moclobemide Tab 300 mg ........................................................................... 18.80 60 ✔ GenRx Moclobemide FLUOROURACIL SODIUM Inj 50 mg per ml, 10 ml – PCT only – Specialist ......................... 4.95 1 ✔ Fluorouracil Ebewe Note – Fluorouracil Ebewe inj 50 mg per ml, 10 ml, 5 injection pack listed 1 May 2010.

138

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 December 2010

27 OMEPRAZOLE, AMOXYCILLIN AND CLARITHROMYCIN Omeprazole cap 20 mg × 14, amoxycillin cap 500 mg × 28 and clarithromycin tab 500 mg × 14 .................................. 55.00 HEPARIN SODIUM Inj 5,000 iu per ml, 5 ml .......................................................... 43.67 KETOCONAZOLE Crm 2% ..................................................................................... 1.00 (9.50) a) Only on a prescription b) Not in combination

1 OP 10 15 g OP

✔ Losec Hp7 OAC ✔ Multiparin

43 60

Nizoral

179

ENTERAL FEED 1KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid ........................................................................................ 1.24 250 ml OP ✔ Isosource HN 5.29 1,000 ml OP ✔ Isosource HN RTH ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid .................................................................................... 1.24 250 ml OP ✔ Fibersource HN 5.29 1,000 ml OP ✔ Fibersource HN RTH ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid ........................................................................................ 7.00 1,000 ml OP ✔ Isosource 1.5 ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid (vanilla) .......................................................................... 1.33 237 ml OP ✔ Resource Plus FOOD THICKENER – Special Authority see SA0595 – Hospital pharmacy [HP3] Powder ..................................................................................... 3.80 250 g OP ✔ Resource Thicken Up

179

179 180 181

Effective 1 January 2011

25 SODIUM ALGINATE ❋ Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) .................................................................. 1.50 (8.64) ZINC OXIDE Oint zinc oxide with balsam peru ............................................... 4.50 (6.67) Suppos zinc oxide with balsam peru ......................................... 4.47 (6.49) MULTIVITAMINS – Special Authority see SA0963 – Retail pharmacy Powder .................................................................................. 36.00 Note – Paediatric Seravit powder 200 g OP subsidised from 1 July 2010. CICLOPIROXOLAMINE a) Only on a prescription b) Not in combination Crm 1% ..................................................................................... 1.00 (12.82)

S29

500 ml Gaviscon 50 g OP Anusol 12 Anusol 100 g OP ✔ Paediatric Seravit

20 g OP Batrafen

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 January 2011 (continued)

63 SODIUM HYPOCHLORITE – Subsidy by endorsement Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ❋ Soln ......................................................................................... 2.71 2,500 ml

✔ Janola

DIPHEMANIL METHYLSULPHATE – Subsidy by endorsement Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. Powder 2% ............................................................................... 6.81 50 g OP (13.54) Prantal GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription ❋ Lotn 5% with paraffin liq 5% and cetyl alcohol 2% ..................... 1.40 250 ml (8.10) OILY CREAM ❋ Crm BP .................................................................................... 2.80 (13.60) (15.40) ZINC Crm BP .................................................................................... 6.55 (12.00) TAR WITH CADE OIL Bath emul 7.5% coal tar, 2.5% cade oil, 7.5% compound ........... 9.70 (29.60) HYDROGEN PEROXIDE ❋ Soln 20 vol – Maximum of 500 ml per prescription .................... 3.13 (7.00) APPLICATOR When ordered with a spermicide. ❋ Applicator – Up to 1 dev available on a PSO ............................... 4.34 DIAPHRAGM – Up to 1 dev available on a PSO ❋ Diaphragm, 55 mm ................................................................. 42.90 ❋ Diaphragm, 60 mm ................................................................. 42.90 ❋ Diaphragm, 65 mm ................................................................. 42.90 ❋ Diaphragm, 70 mm ................................................................. 42.90 ❋ Diaphragm, 75 mm ................................................................. 42.90 ❋ Diaphragm, 80 mm ................................................................. 42.90 ❋ Diaphragm, 85 mm ................................................................. 42.90 ❋ Diaphragm, 90 mm ................................................................. 42.90 One of each size is permitted on a PSO. 500 g David Craig PSM 500 g PSM 350 ml Polytar Emollient 500 ml PSM

1 1 1 1 1 1 1 1 1

✔ Ortho ✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil

NONOXYNOL-9 Jelly 2% – Up to 108 g available on a PSO ............................... 10.95 Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

108 g OP

✔ Gynol II

▲

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 January 2011 (continued)

175 176 179 180 185 PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA0896 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.60 200 ml OP ✔ Nutrini Energy RTH PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0896 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.07 200 ml OP ✔ Nutrini RTH ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid ........................................................................................ 1.75 250 ml OP ✔ Isosource 1.5 ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.33 237 ml OP ✔ Resource Plus AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0962 – Retail pharmacy See prescribing guideline Powder .................................................................................. 58.44 250 g OP ✔ Metabolic Mineral Mixture Note – Metabolic Mineral Mixture powder 100 g OP subsidised from 1 July 2010.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part I

Effective 1 July 2010

“DV Pharmaceutical” means a discretionary variance Pharmaceutical;, that does not have HSS but is used in place of one that does. Usually this means it and which: (a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or (b)is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical. Where this is not the case, a note will be included with the listing of the HSS pharmaceutical.

Section H changes to Part II

Effective 1 July 2010

AMLODIPINE (new listing) Tab 5 mg........................................Norvasc Tab 10 mg......................................Norvasc AMLODIPINE (HSS suspended) Tab 5 mg........................................Apo-Amlodipine Tab 10 mg......................................Apo-Amlodipine 22.82 34.85 7.33 11.79 30 30 100 100 1% 1% Feb-09 Feb-09 Calvasc Norvasc Calvasc Norvasc

Note – HSS for Apo-Amlodipine tab 5 mg and 10 mg has been suspended due to an out-of-stock. AMOXYCILLIN (expiry of HSS) Cap 250 mg ...................................Apo-Amoxi Cap 500 mg ...................................Apo-Amoxi 17.30 27.25 500 500 1% 1% Sept-07 Sept-07 Amoxil Moxlin Ospamox Amoxil Moxlin Ospamox Apo-Bisacodyl Dulcolax (B) (B) (B) (B) (B) (B) Calci-Tab Effervescent

BISACODYL ( price, continuation of HSS) Tab 5 mg........................................Lax-Tabs BUPIVACAINE HYDROCHLORIDE (expiry of HSS) Inf 0.125%, 100 ml theatre pack .....Marcain Inf 0.125%, 200 ml theatre pack .....Marcain Inf 0.25%, 100 ml theatre pack .......Marcain Inj 0.375%, 20 ml theatre pack .......Marcain Inj 0.5%, 4 ml .................................Marcain Isobaric Inj 0.5%, 8% glucose, 4 ml .............Marcain Heavy

4.99

200

Sept-10

109.39 146.23 132.42 56.20 29.35 24.50

5 5 5 5 5 5

1% 1% 1% 1% 1% 1% 1%

Aug-07 Aug-07 Aug-07 Aug-07 Aug-07 Aug-07 Sept-08

CALCIUM CARBONATE (amended chemical name and presentation) Tab eff 1.75 g (1 g elemental)........Calsource 6.54 30

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

CAPTOPRIL (expiry of HSS) Tab 12.5 mg...................................Apo-Captopril Tab 25 mg......................................Apo-Captopril Tab 50 mg......................................Apo-Captopril 10.40 13.40 19.00 500 500 500 1% 1% 1% Dec-07 Dec-07 Dec-07 Capoten Captohexal Capoten Captohexal Capoten Captohexal Clorotir CEC Suspension Clorotir

CEFACLOR MONOHYDRATE (expiry of HSS) Cap 250 mg ...................................Ranbaxy-Cefaclor 28.90 CEFACLOR MONOHYDRATE ( price, continuation of HSS) Grans for oral liq 125 mg per 5 ml ..Ranbaxy-Cefaclor 3.53 CHLORHEXIDINE (new listing) Soln 5%, 500 ml .............................healthE CHLORHEXIDINE GLUCONATE (new listing) Obstetric lotion 1%, 200 ml.............healthE CHLORHEXIDINE IN ALCOHOL (new listing) Soln 0.5% with 70% alcohol, 100 ml (tinted pink) ...................healthE Soln 0.5% with 70% alcohol, 100 ml (tinted red) ....................healthE Soln 0.5% with 70% alcohol, 500 ml (tinted pink) ...................healthE Soln 0.5% with 70% alcohol, 500 ml (tinted red) ....................healthE Soln 2% with 70% alcohol, 100 ml (tinted pink) ...................healthE Soln 2% with 70% alcohol, 100 ml (tinted red) ....................healthE CLARITHROMYCIN (expiry of HSS) Grans for oral liq 125 mg per 5 ml ..Klacid Tab 250 mg....................................Klamycin CLOMIPHENE CITRATE (new listing) Tab 50 mg......................................Serophene

100 100 ml

1% 1%

Sept-07 Sept-10

186.00 81.00

12 12

31.80 34.80 65.40 70.80 42.48 46.32 23.12 7.75

12 12 12 12 12 12 70 ml 14 1% 1% Sept-07 Mar-08 (B) Clarac Klacid

29.84

10 1% 1% Sept-10 Sept-10 Canesten Clocreme Clotrimaderm Canesten Clocreme Clotrimaderm

CLOTRIMAZOLE (amended description,  price and continuation of HSS) Vaginal crm 1% with applicator(s) ...Clomazol 1.30 35 g Vaginal crm 2% with applicator(s) ...Clomazol 2.50 20 g

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

CODEINE PHOSPHATE (expiry of HSS) Tab 15 mg......................................PSM Tab 30 mg......................................PSM Tab 60 mg......................................PSM COLCHICINE (continuation of HSS) Tab 500 µg ....................................Colgout COLISTIN SULPHOMETHATE (expiry of HSS) Inj 150 mg......................................Colistin-Link CYCLOPHOSPHAMIDE (continuation of HSS) Tab 50 mg......................................Cycloblastin DANTHRON WITH POLOXAMER (new listing) Oral liq 25 mg with poloxamer 200 mg per 5 ml ........................Pinorax DESFERRIOXAMINE MESYLATE (expiry of HSS) Inj 500 mg .....................................Mayne DEXAMETHASONE (new listing) Eye drops 0.1% ..............................Maxidex DEXAMPHETAMINE SULPHATE (expiry of HSS) Tab 5 mg........................................PSM 5.39 8.25 17.76 9.60 65.00 25.71 100 100 100 100 1 50 1% 1% 1% 1% 1% 1% Mar-08 Mar-08 Mar-08 Sept-10 Dec-07 Sept-10 (B) (B) (B) (B) (B) Endoxan

9.50 99.00 4.50 16.50

300 ml 10 5 ml 100 1% 1% 1% 1% 1% Sept-07 Sept-10 Apr-08 Jul-10 Jul-10 (B) (B) (B) Docetaxel Winthrop Taxotere Docetaxel Winthrop Taxotere

DOCETAXEL (HSS reinstated) Inj 20 mg........................................Docetaxel 325.00 1 Ebewe Inj 80 mg........................................Docetaxel 1,300.00 1 Ebewe Note – HSS for Docetaxel Ebewe inj 20 mg and 80 mg reinstated 1 July 2010. DOXAZOSIN MESYLATE (expiry of HSS) Tab 2 mg .......................................Apo-Doxazosin Tab 4 mg........................................Apo-Doxazosin FERROUS FUMARATE (amended presentation) Tab 200 mg (65 mg elemental) ....Ferro-tab 22.85 30.26 4.35 500 500 100

1% 1%

Jan-08 Jan-08

Dosan Dosan

FERROUS FUMARATE WITH FOLIC ACID (amended presentation) Tab 310 mg (100 mg elemental) with folic acid 350 µg ................Ferro-F-Tabs 4.75 FERROUS SULPHATE (amended presentation, continuation of HSS) Oral liquid 30 mg per 1 ml 150 mg per 5 ml (6 mg elemental per 1 ml) ........Ferodan 10.30

500 ml

Sept-10

Ferro-liquid

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE (expiry of HSS) Oint 950 μg, wtih fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g .................................Ultraproct 6.35 30 g 1% Sept-07 Proctosedyl Xyloproct Suppos 630 μg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg..........................................Ultraproct 2.66 12 1% Sept-07 Proctosedyl Xyloproct FLUOROURACIL SODIUM (expiry of HSS) Inj 25 mg per ml, 100 ml ................Mayne Inj 50 mg per ml, 10 ml ..................Fluorouracil Ebewe Inj 50 mg per ml, 20 ml ..................Fluorouracil Ebewe Inj 50 mg per ml, 50 ml ..................Fluorouracil Ebewe Inj 50 mg per ml, 100 ml ................Fluorouracil Ebewe 13.55 4.95 8.60 21.50 43.00 1 1 1 1 1 1% 1% 1% 1% 1% Oct-07 Oct-07 Oct-07 Oct-07 Oct-07 (B) Mayne Mayne Mayne (B)

FLUOXETINE HYDROCHLORIDE ( price and expiry of HSS) Cap 20 mg .....................................Fluox 2.89

Mar-08

Apo-Fluoxetine Flexetor Prozac

Note – Fluox cap 20 mg, 90 cap pack, to be delisted 1 September 2010. FLUOXETINE HYDROCHLORIDE (new listing) Cap 20 mg .....................................Fluox 2.70 84 1% Sept-10 Flexetor Dr Reddy’s Prozac (B) Fucidin Fucidin Gemzar Hospira Gemzar Hospira Nurofen

FLUOXETINE HYDROCHLORIDE ( price, amended presentation, continuation of HSS) Tab dispersible 20 mg, scored ......Fluox 2.50 30 1% FUSIDIC ACID ( price, continuation of HSS) Crm 2% .........................................Foban Oint 2% .........................................Foban 3.25 3.25 15 g 15 g 1 1 1% 1% 1% 1%

Sept-10 Sept-10 Sept-10 Sept-10 Sept-10

GEMCITABINE HYDROCHLORIDE ( price, continuation of HSS) Inj 200 mg......................................Gemcitabine 12.50 Ebewe Inj 1 g.............................................Gemcitabine 62.50 Ebewe IBUPROFEN ( price, continuation of HSS) Oral liq 100 mg per 5 ml .................Fenpaed IODINE WITH ALCOHOL (new listing) Soln 1% with 70% alcohol, 100 ml ......................................healthE Products with Hospital Supply Status (HSS) are in bold. 2.69

200 ml

Sept-10

111.60

12 (B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

IPRATROPIUM BROMIDE (expiry of HSS) Nebuliser soln 250 µg per ml, 1 ml ...........................................Ipratropium Steri-Neb Nebuliser soln 250 µg per ml, 2 ml ...........................................Ipratropium Steri-Neb ISOPROPYL ALCOHOL (new listing) Soln 70%, 500 ml ..........................healthE ITRACONAZOLE (expiry of HSS) Cap 100 mg ...................................Sporanox LACTULOSE (expiry of HSS) Oral liq 10 g per 15 ml ....................Duphalac LEVOBUNOLOL (expiry of HSS) Eye drops 0.25% ...........................Betagan Eye drops 0.5% .............................Betagan LIGNOCAINE HYDROCHLORIDE (expiry of HSS) Inj 0.5%, 5 ml .................................Xylocaine Pump spray 10%, 50 ml CFC-free ...Xylocaine

4.30 5.25

20 20

1% 1%

Sept-07 Sept-07

Ipra 250 Ipra 500

67.80 23.70 6.65

12 15 1000 ml 1% 1% Aug-07 Dec-07 Itrazole Actilax Laevolac (B) Alcon-Levobunolol (B) (B)

7.00 7.00 44.10 60.00

5 ml 5 ml 50 1

1% 1% 1% 1%

Aug-07 Aug-07 Sept-07 Aug-07

LIGNOCAINE HYDROCHLORIDE WITH ADRENALINE (expiry of HSS) Inj 1% with 1:100,000 of adrenaline, 5 ml .........................Xylocaine 18.00 10 Inj 1% with 1:200,000 of adrenaline, 20 ml .......................Xylocaine 44.00 5 Inj 2% with 1:200,000 of adrenaline, 20 ml .......................Xylocaine 49.50 5 LIGNOCAINE WITH PRILOCAINE (expiry of HSS) Crm 2.5% with prilocaine 2.5%, 5 g ...................................EMLA Crm 2.5% with prilocaine 2.5%, 30 g ................................EMLA LOPINAVIR WITH RITONAVIR (new listing) Tab 100 mg with ritonavir 25 mg ....Kaletra

1% 1% 1%

Aug-07 Aug-07 Aug-07

(B) (B) (B)

41.00 41.00 183.75

5 1 60

1% 1%

Sept-07 Sept-07

(B) (B)

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

LORATADINE ( price, continuation of HSS) Oral liq 1 mg per ml ........................Lorapaed 3.10 100 ml 100 1% 1% Sept-10 Dec-07 Claratyne Lorafast Apo-Loratadine Aridine Arrow-Loratadine Claratyne Lorastyne Lora-tabs Lorfast Tirlor Cycrin Cycrin Cycrin (B) (B) (B) (B) Pallidone

Tab 10 mg......................................Loraclear 2.09 Hayfever Relief

MEDROXYPROGESTERONE ACETATE (expiry of HSS) Tab 2.5 mg.....................................Provera Tab 5 mg........................................Provera Tab 10 mg......................................Provera Tab 100 mg....................................Provera Tab 200 mg....................................Provera MESNA (expiry of HSS) Inj 100 mg per ml, 4 ml ..................Uromitexan Inj 100 mg per ml, 10 ml ................Uromitexan METHADONE HYDROCHLORIDE (expiry of HSS) Tab 5 mg........................................Methatabs

3.09 13.06 6.85 96.50 70.50 109.63 251.73 2.10 2.18 2.18 2.74 2.74 4.71 4.71 8.51 8.51

30 100 30 100 30 15 15 10 30 30 30 30 30 30 30 30 1

1% 1% 1% 1% 1% 1% 1% 1%

Sept-07 Sept-07 Sept-07 Sept-07 Sept-07 Oct-07 Oct-07 Nov-07

METOPROLOL SUCCINATE ( price) Tab long-acting 23.75 mg ..............Metoprolol-AFT CR Betaloc CR Tab long-acting 47.5 mg.................Metoprolol-AFT CR Betaloc CR Tab long-acting 95 mg....................Metoprolol-AFT CR Betaloc CR Tab long-acting 190 mg .................Metoprolol-AFT CR Betaloc CR MITOZANTRONE (expiry of HSS) Inj 2 mg per ml, 5 ml ......................Mitozantrone Ebewe MITOZANTRONE ( price, continuation of HSS) Inj 2 mg per ml, 10 ml ....................Mitozantrone Ebewe NADOLOL (expiry of HSS) Tab 40 mg......................................Apo-Nadolol Tab 80 mg......................................Apo-Nadolol NALTREXONE HYDROCHLORIDE (expiry of HSS) Tab 50 mg......................................ReVia

110.00

Feb-08

Onkotrone

100.00

Sept-10

Onkotrone

14.97 22.19 180.00

100 100 30

1% 1% 1%

Sept-07 Sept-07 Sept-07

Corgard Corgard (B)

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

NAPROXEN SODIUM (expiry of HSS) Tab 275 mg....................................Sonaflam NEOSTIGMINE METHYLSULPHATE (expiry of HSS) Inj 2.5 mg per ml, 1 ml ...................AstraZeneca NYSTATIN (expiry of HSS) Cap 500,000 u ...............................Nilstat Tab 500,000 u................................Nilstat ONDANSETRON HYDROCHLORIDE (expiry of HSS) Tab disp 4 mg ................................Zofran Zydis Tab disp 8 mg ................................Zofran Zydis Tab 4 mg........................................Zofran Tab 8 mg........................................Zofran OXYBUTYNIN (expiry of HSS) Oral liq 5 mg per 5 ml .....................Apo-Oxybutynin Tab 5 mg........................................Apo-Oxybutynin OXYCODONE HYDROCHLORIDE (expiry of HSS) Inj 10 mg per ml, 1 ml ....................OxyNorm Inj 10 mg per ml, 2 ml ....................OxyNorm Oral liq 5 mg per 5 ml .....................OxyNorm PANTOPRAZOLE (expiry of HSS) Inj 40 mg........................................Pantocid PANTOPRAZOLE ( price, continuation of HSS) Tab 20 mg......................................Dr Reddy’s Pantoprazole Tab 40 mg......................................Dr Reddy’s Pantoprazole 6.00 20.30 11.64 9.60 17.18 20.43 17.18 33.89 50.40 44.79 14.40 28.80 11.20 8.75 1.23 1.54 120 50 50 50 10 10 10 20 473 ml 500 5 5 250 ml 1 28 28 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% Feb-08 Sept-07 Sept-07 Sept-07 Aug-07 Aug-07 Aug-07 Aug-07 Dec-07 Dec-07 Nov-07 Nov-07 Nov-07 May-09 Sept-10 Sept-10 Synflex (B) (B) Mycostatin (B) (B) (B) (B) (B) (B) (B) (B) (B) Somac Somac Somac

PAROXETINE HYDROCHLORIDE ( price, continuation of HSS) Tab 20 mg......................................Loxamine 2.38 PHENOXYMETHYLPENICILLIN (PENICILLIN V) (expiry of HSS) Cap potassium salt 250 mg ............Cilicaine VK 4.29 Cap potassium salt 500 mg ............Cilicaine VK 8.15

Sept-10

Aropax Arrow-Paroxetine (B) (B) (B) (B) (B) (B) (B)

50 50

1% 1% 1% 1% 1% 1% 1%

Sept-07 Sept-07 Sept-10 Sept-10 May-08 May-08 May-08

PHENOXYMETHYLPENICILLIN (PENICILLIN V) (continuation of HSS) Grans for oral liq 125 mg per 5 ml .......AFT 1.68 100 ml Grans for oral liq 250 mg per 5 ml ( price)............................AFT 1.78 100 ml PRAZOSIN HYDROCHLORIDE (expiry of HSS) Tab 1 mg........................................Apo-Prazo Tab 2 mg........................................Apo-Prazo Tab 5 mg........................................Apo-Prazo Products with Hospital Supply Status (HSS) are in bold. 5.53 7.00 11.70 100 100 100

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

PRILOCAINE HYDROCHLORIDE (expiry of HSS) Inj 0.5%, 50 ml ...............................Citanest Inj 2%, 5 ml ....................................Citanest RANITIDINE HYDROCHLORIDE (expiry of HSS) Oral liq 150 mg per 10 ml ...............Peptisoothe 80.00 30.90 7.95 5 10 300 ml 1% 1% 1% Aug-07 Aug-07 Jan-08 (B) (B) Zantac Requip Requip Requip Requip (B) (B) (B) (B) (B) (B) (B) (B)

ROPINIROLE HYDROCHLORIDE (amended chemical name,  price, continuation of HSS) Tab 0.25 mg ..................................Ropin 6.20 84 1% Sept-10 Tab 1 mg .......................................Ropin 15.95 84 1% Sept-10 Tab 2 mg .......................................Ropin 24.95 84 1% Sept-10 Tab 5 mg .......................................Ropin 38.00 84 1% Sept-10 ROPIVACAINE HYDROCHLORIDE (expiry of HSS) Inj 2 mg per ml, 10 ml ....................Naropin Inj 2 mg per ml, 20 ml ....................Naropin Inf 2 mg per ml, 100 ml ..................Naropin Inf 2 mg per ml, 200 ml ..................Naropin Inj 7.5 mg per ml, 10 ml .................Naropin Inj 7.5 mg per ml, 20 ml .................Naropin Inj 10 mg per ml, 10 ml ..................Naropin Inj 10 mg per ml, 20 ml ..................Naropin 19.75 33.20 104.00 184.00 35.00 62.45 41.10 74.20 5 5 5 5 5 5 5 5 1% 1% 1% 1% 1% 1% 1% 1% Aug-07 Aug-07 Aug-07 Aug-07 Aug-07 Aug-07 Aug-07 Aug-07

ROPIVACAINE HYDRCHLORIDE WITH FENTANYL (expiry of HSS) Inf 2 mg per ml with 2 µg of fentanyl per ml, 100 ml ...........................Naropin 145.20 Inf 2 mg per ml with 2 µg of fentanyl per ml, 200 ml ...........................Naropin 262.60 SALBUTAMOL ( price, continuation of HSS) Oral liq 2 mg per 5 ml .....................Salapin SODIUM CITRO-TARTRATE (expiry of HSS) Gran eff 4 g sachets .......................Ural SORBOLENE WITH GLYCERINE (new listing) Crm with 10% glycerine, 500 ml ......................................healthE 1.99 2.75

5 5 150 ml 28

1% 1% 1% 1%

Aug-07 Aug-07 Sept-10 Sept-07

(B) (B) Ventolin Citravescent

87.60

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 July 2010 (continued)

SPECIAL FOOD SUPPLEMENT (new listing) Amino acid based elemental formula, powder (unflavoured) .....Vivonex Pediatric 6.00 Fat free arginine supplement, powder (orange) ..........................Resource Arginaid 2.15 Oral elemental feed 1 kcal/ml liquid (vanilla) ...............................Peptamen OS 1.0 4.95 Oral elemental feed 1 kcal/ml, powder (unflavoured) ..................Vivonex TEN 4.50 Oral feed 1 kcal/ml, liquid (vanilla) .......................................Resource Diabetic 2.10 Oral supplement 1 kcal/ml, powder (chocolate) .....................Sustagen Hospital 10.22 Formula Oral supplement 1 kcal/ml, powder (vanilla)...........................Sustagen Hospital 10.22 Formula Protein supplement powder ...........Resource 8.95 Beneprotein Renal oral feed 2 kcal/ml, liquid (vanilla) ..............................Novasource Renal 3.31 SPECIAL FOOD SUPPLEMENT ( price) Liquid, 237 ml ................................Impact Advanced 4.00 Recovery Chocolate Impact Advanced 4.00 Recovery Vanilla SPIRONOLACTONE ( price, addition of HSS) Tab 25 mg......................................Spirotone Tab 100 mg....................................Spirotone SUXAMETHONIUM CHLORIDE (expiry of HSS) Inj 50 mg per ml, 2 ml ....................AstraZeneca SYRUP (PHARMACEUTICAL GRADE) (expiry of HSS) Liq .................................................Midwest ZINC SULPHATE (amended presentation) Cap 220 137.4 mg (50 mg elemental) ...................Zincaps 4.60 15.15 95.00 21.75

48.5 g 9.2 g 237 ml 80.4 g 237 ml 900 g 900 g 227 g 237 ml 237 ml 237 ml

100 100 50

1% 1% 1%

Sept-10 Sept-10 Aug-07 Sept-07

(B) (B) (B) David Craig

2,000 ml 1%

10.00

100

Dec-08

(B)

Effective 1 June 2010

BECLOMETHASONE DIPROPIONATE ( price) Metered aqueous nasal spray, 50 µg per dose ..........................Alanase Metered aqueous nasal spray, 100 µg per dose ........................Alanase

4.00 4.81

200 dose 200 dose

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 June 2010 (continued)

CYTARABINE Inj 100 mg......................................Pfizer 76.00 5 1% Aug-10 Mayne Mayne Mayne Mayne

CYTARABINE (new listing and amended description) Inj 500 mg 100 mg per ml, 5 ml .....Pfizer 18.15 1 1% Aug-10 Inj 1 g 100 mg per ml, 10 ml ..........Pfizer 37.00 1 1% Aug-10 Inj 2 g 100 mg per ml, 20 ml ..........Pfizer 31.00 1 1% Aug-10 Note – Mayne’s brand of cytarabine inj 500 mg, 1 g and 2 g to be delisted 1 August 2010. DEXAMETHASONE SODIUM PHOSPHATE (amended brand name and addition of HSS) Inj 4 mg per ml, 1 ml ......................Hospira Mayne 21.50 5 1% Inj 4 mg per ml, 2 ml ......................Hospira Mayne 31.00 5 1% ENALAPRIL Tab 5 mg........................................Arrow-Enalapril Tab 10 mg......................................Arrow-Enalapril Tab 20 mg......................................Arrow-Enalapril 1.98 2.44 3.24 90 90 90 1% 1% 1% Aug-10 Aug-10 Aug-10 Aug-10 Aug-10

(B) (B) m-Enalapril Redopril Renitec m-Enalapril Redopril Renitec m-Enalapril Redopril Renitec Camptosar DBL Irinotecan Irinotecan Actavis 40 Mylan Camptosar DBL Irinotecan Irinotecan Actavis 100 Mylan

IRINOTECAN Inj 20 mg per ml, 2 ml ....................Irinotecan-Rex

41.00

Aug-10

Inj 20 mg per ml, 5 ml ....................Irinotecan-Rex 100.00

Aug-10

Note – Camptosar inj 20 mg per ml, 2 ml and 5 ml to be delisted 1 August 2010. PROPOFOL ( price) Inj 1%, 20 ml .................................Diprivan Provive 1% Inj 1%, 50 ml .................................Diprivan Provive 1% Inj 1%, 100 ml ................................Diprivan Provive 1% RISPERIDONE ( price) Tab 0.5 mg.....................................Ridal Ridal Tab 1 mg........................................Ridal Tab 2 mg........................................Ridal Tab 3 mg........................................Ridal Tab 4 mg........................................Ridal Products with Hospital Supply Status (HSS) are in bold. 10.21 10.21 5.56 5.56 9.28 9.28 1.17 3.51 6.00 11.00 15.00 20.00 5 5 1 1 1 1 20 60 60 60 60 60 (B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 June 2010 (continued)

TRAMADOL HYDROCHLORIDE Cap 50 mg .....................................Arrow-Tramadol Note – Tramal cap 50 mg to be delisted 1 August 2010. VINCRISTINE SULPHATE ( price, amended brand name and addition of HSS) Inj 1 mg per ml, 1 ml ......................Hospira Mayne 108.00 5 5 Inj 1 mg per ml, 2 ml ......................Hospira Mayne 116.00 1% 1% Aug-10 Aug-10 (B) (B) 6.95 100 1% Aug-10 AFT Tramal Tramedo

Effective 28 May 2010

ATENOLOL Tab 50 mg......................................Atenolol Tablet USP 12.36 Anselol Apo-Atenolol Atehexal Global Atenolol Tab 100 mg....................................Atenolol Tablet USP21.46 1,000 1% May-10 Anselol Apo-Atenolol Atehexal Global Atenolol Note – HSS status has been transferred to Atenolol Tablet USP tab 50 mg and 100 mg from Pacific Atenolol. Pacific Atenolol remains listed without HSS status. 1,000 1% May-10

Effective 1 May 2010

BENDROFLUAZIDE Tab 2.5 mg.....................................Arrow7.58 Bendrofluazide Tab 5 mg........................................Arrow11.75 Bendrofluazide 500 500 1% 1% Jul-10 Jul-10 Neo-Naclex Neo-Naclex

CISPLATIN ( price and addition of HSS) Inj 1 mg per ml, 50 ml ....................Cisplatin Ebewe 15.00 1 1% Jul-10 Inj 1 mg per ml, 100 ml ..................Cisplatin Ebewe 21.00 1 1% Jul-10 Note – Mayne cisplatin inj 1 mg per ml, 50 ml and 100 mg, to be delisted 1 July 2010. CLINDAMYCIN (addition of HSS) Inj phosphate 150 mg per ml, 4 ml ..................Dalacin C

DBL Cisplatin DBL Cisplatin

16.00

1 500

Jul-10

(B)

CLOMIPRAMINE HYDROCHLORIDE Tab 25 mg......................................Clopress 26.00 Note – Clopress tab 25 mg to be delisted 1 July 2010. DANAZOL Cap 200 mg ...................................D-Zol 29.35 Note– D-Zol cap 200 mg to be delisted 1 November 2010.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 May 2010 (continued)

DOCUSATE SODIUM (correction of presentation) Cap tab 50 mg ...............................Laxofast 50 Cap tab 120 mg .............................Laxofast 120 3.95 5.49 100 100 1% 1% Jun-10 Jun-10 Coloxyl Coloxyl Mayne

FLUOROURACIL SODIUM (addition of new pack size) Inj 50 mg per ml, 10 ml ..................Fluorouracil 24.75 5 1% Oct-07 Ebewe Note – Fluorouracil Ebewe inj 50 mg per ml, 10 ml, 1 injection pack, to be delisted 1 July 2010. FUROSEMIDE Tab 500 mg....................................Diurin 500 12.00 Note – Diurin 500 tab 500 mg to be delisted 1 July 2010. LIGNOCAINE Gel 2%, 10 ml urethral syringe .......Pfizer MEDROXYPROGESTERONE ACETATE (addition of HSS) Inj 150 mg per ml, 1 ml, syringe .....Depo-Provera 43.26 7.15 100

10 1 30 100 30 100 30 1% 1% 1% 1% 1% 1% Jul-10 Jul-10 Jul-10 Jul-10 Jul-10 Jul-10 May-10 May-10 (B) Cycrin Cycrin Cycrin (B) (B) GenRx Moclobemide GenRx Moclobemide

MEDROXYPROGESTERONE ACETATE (continuation of HSS) Tab 2.5 mg.....................................Provera 3.09 Tab 5 mg........................................Provera 13.06 Tab 10 mg......................................Provera 6.85 Tab 100 mg....................................Provera 96.50 Tab 200 mg....................................Provera 70.50

MOCLOBEMIDE (reinstatement of HSS) Tab 150 mg....................................Apo69.23 500 1% Moclobemide Tab 300 mg....................................Apo31.33 100 1% Moclobemide Note – GenRx Moclobemide tab 150 mg and 300 mg to be delisted 1 May 2010. TENOXICAM Inj 20 mg........................................AFT TESTOSTERONE UNDECANOATE Cap 40 mg ....................................ArrowTestosterone 9.95 79.92 1 100 1% 1%

Jul-10 Jul-10

(B) Andriol Testocaps Panteston

Effective 1 April 2010

AMBRISENTAN Tab 5 mg........................................Volibris Tab 10 mg......................................Volibris BISACODYL Suppos 5 mg..................................Dulcolax Suppos 10 mg................................Dulcolax CHLORAMPHENICOL ( price) Eye drops 0.5% .............................Chlorsig Products with Hospital Supply Status (HSS) are in bold. 4,585.00 4,585.00 3.00 3.00 2.40 30 30 6 6 10 ml (B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 April 2010 (continued)

CIPROFLOXACIN ( price and addition of HSS) Inj 2 mg per ml, 100 ml ..................Aspen Ciprofloxacin 41.00 10 1% Jun-10 Ciproxin DBL DP-Cipro Topistin Ufexil

DANAZOL Cap 200 mg ...................................Azol DIHYDROCODEINE TARTRATE Tab long-acting 60 mg....................DHC Continus DOCUSATE SODIUM Tab 50 mg......................................Laxofast 50 Tab 120 mg....................................Laxofast 120

97.83 27.27 3.95 5.49

100 60 100 100 1% 1% 1% Jun-10 Jun-10 Jun-10 (B) Coloxyl Coloxyl

DOCUSATE SODIUM WITH SENNOSIDES ( price and addition of HSS) Tab 50 mg with total sennosides 8 mg .......................Laxsol 6.38 200 HYDROCORTISONE Crm 1% ..........................................Pharmacy Health 3.75 100 g

Jun-10

Coloxyl with Senna

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN (Amended chemical name) Crm 1% with natamycin 1% and neomycin sulphate 0.5% ............Pimafucort 2.79 15 g Oint 1% with natamycin 1% and neomycin sulphate 0.5% ............Pimafucort 2.79 15 g OMEPRAZOLE Cap 10 mg .....................................Dr Reddy’s 2.00 28 1% May-09 Losec Omeprazole Omezol Cap 20 mg .....................................Dr Reddy’s 2.85 28 1% May-09 Losec Omeprazole Omezol Cap 40 mg .....................................Dr Reddy’s 3.35 28 1% May-09 Losec Omeprazole Omezol Note – Dr Reddy’s Omeprazole cap 10 mg, 20 mg and 40 mg, 28 cap packs, to be delisted 1 June 2010. Please note that the 30 capsule packs remain listed. PIPERACILLIN SODIUM WITH TAZOBACTAM SODIUM Inj 4 g with tazobactam sodium 500 mg .........................Tazocin EF

12.00

Jun-10

DBL Zobacin

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 April 2010 (continued)

TOPIRAMATE Tab 25 mg......................................Arrow -Topiramate Tab 50 mg......................................Arrow -Topiramate Tab 100 mg....................................Arrow -Topiramate Tab 200 mg....................................Arrow -Topiramate TRANEXAMIC ACID ( price and addition of HSS) Tab 500 mg....................................Cyclokapron ZIDOVUDINE (AZT) Cap 100 mg ...................................Retrovir Oral liq 10 mg per ml ......................Retrovir 11.07 18.81 31.99 55.19 60 60 60 60

32.92 145.00 29.00

100 100 200 ml

1% 1% 1%

Jun-10 Jun-10 Jun-10

(B) (B) (B)

Section H changes to Part IV

Effective 1 April 2010

CLOPIDOGREL Tab 75 mg Plavix Up to 4 weeks supply post stenting. Not to be funded for acute coronary syndrome or transient ischaemic attacks.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands Symbols 3TC ................................................................... 39 A Alanase........................................................ 38, 57 Alendronate sodium ........................................... 30 Alendronate sodium with cholecalciferol ............. 30 Alpha-Bromocriptine .......................................... 42 Alpha-Keri Lotion ............................................... 43 Ambrisentan ...................................................... 60 Aminoacid formula with minerals without phenylalanine ............................................ 22, 48 Amlodipine................................................... 21, 49 Amoxycillin .................................................. 43, 49 Andriol Testocaps ........................................ 36, 45 Antiretrovirals ..................................................... 24 Anusol ............................................................... 46 Apo-Amlodipine ................................................. 49 Apo-Amoxi......................................................... 49 Apo-Captopril ..................................................... 50 Apo-Diclo SR ..................................................... 45 Apo-Doxazosin................................................... 51 Apo-Moclobemide.............................................. 60 Apo-Nadolol ....................................................... 54 Apo-Oxybutynin ................................................. 55 Apo-Prazo.......................................................... 55 Applicator .......................................................... 47 Aquasun Sensitive SPF 30+ .............................. 43 Arrow ................................................................ 22 Arrow-Bendrofluazide ................................... 23, 59 Arrow-Cabergoline ............................................. 36 Arrow-Enalapril ............................................ 22, 58 Arrow-Lamotrigine ............................................. 43 Arrow-Metformin................................................ 42 Arrow-Testosterone ..................................... 23, 60 Arrow-Topiramate .............................................. 62 Arrow-Tramadol ........................................... 22, 59 Aspec 300 ......................................................... 36 Aspen Ciprofloxacin ........................................... 61 Aspirin ......................................................... 35, 36 Atenolol ................................................. 22, 42, 59 Atenolol Tablet USP...................................... 22, 59 Atropine sulphate ............................................... 41 Azol ................................................................... 61 B Batrafen ............................................................. 46 Beclomethasone dipropionate....................... 38, 57 Bendrofluazide ................................. 23, 35, 44, 59 Betagan ............................................................. 53 Betaloc CR ................................................... 35, 54 Bisacodyl ............................................... 35, 49, 60 Blenoxane .......................................................... 42 Bleomycin sulphate ............................................ 42 Bromocriptine mesylate...................................... 42 Bupivacaine hydrochloride.................................. 49 C Cabergoline........................................................ 36 Calcitriol ............................................................ 42 Calcitriol-AFT ..................................................... 42 Calci-Tab 500 .................................................... 32 Calci-Tab 600 .................................................... 32 Calcium carbonate ....................................... 32, 49 Calsource .................................................... 32, 49 Capadex............................................................. 44 Captopril ............................................................ 50 Cefaclor monohydrate .................................. 36, 50 Cetomacrogol .................................................... 36 Chloramphenicol ................................................ 60 Chlorhexidine ..................................................... 50 Chlorhexidine gluconate ................... 39, 40, 44, 50 Chlorhexidine in alcohol...................................... 50 Chlorsig ............................................................. 60 Ciclopiroxolamine............................................... 46 Cilicaine VK........................................................ 55 Ciprofloxacin ...................................................... 61 Cisplatin................................................. 37, 39, 59 Cisplatin Ebewe............................................ 39, 59 Citanest ............................................................. 56 Clarithromycin.................................................... 50 Clindamycin ....................................................... 59 Clomazol................................................ 24, 36, 50 Clomiphene citrate ................................. 21, 24, 50 Clomipramine hydrochloride ................... 42, 45, 59 Clopidogrel ........................................................ 62 Clopress ...................................................... 45, 59 Clotrimazole ........................................... 24, 36, 50 Combined oral contraceptives ............................ 29 Cotazym ECS ..................................................... 29 Coal tar ........................................................ 21, 36 Codalgin ............................................................ 42 Codeine phosphate ............................................ 51 Colchicine .......................................................... 51 Colgout .............................................................. 51 Colistin-Link ....................................................... 51 Colistin sulphomethate ....................................... 51 Coloxyl ........................................................ 38, 44 Creon 10000...................................................... 29 Creon Forte ........................................................ 29 Crotamiton ................................................... 38, 44 Cycloblastin ....................................................... 51 Cyclokapron....................................................... 62 Cyclophosphamide ............................................ 51 Cytarabine ................................. 22, 32, 38, 40, 58

Index

Pharmaceuticals and brands D D-Zol ........................................................... 45, 59 Dalacin C ........................................................... 59 Danazol.................................................. 45, 59, 61 Danthron with poloxamer.............................. 21, 51 Dapsone ............................................................ 24 Deca-Durabolin Orgaject .................................... 22 Depo-Provera ..................................................... 60 Derbac-M .......................................................... 29 Desferrioxamine mesylate .................................. 51 Dexamethasone ................................................. 51 Dexamethasone sodium phosphate .............. 40, 58 Dexamphetamine sulphate.................................. 51 Dextrochlorpheniramine maleate ......................... 43 Dextropropoxyphene with paracetamol ............... 44 Dextrose with electrolytes................................... 35 DHC Continus .................................................... 61 Diaphragm ......................................................... 47 Diclax SR ........................................................... 44 Diclofenac Sandoz ............................................. 22 Diclofenac sodium ........................... 22, 42, 44, 45 Diclohexal .......................................................... 45 Dihydrocodeine tartrate ...................................... 61 Dilantin .............................................................. 37 Dilantin Infatab ................................................... 37 Diphemanil methylsulphate ................................. 47 Diprivan ............................................................. 58 Dithranol ............................................................ 41 Diurin 500 .................................................... 45, 60 Docetaxel ..................................................... 37, 51 Docetaxel Ebewe ................................................ 51 Docusate sodium ....................... 32, 38, 44, 60, 61 Docusate sodium with sennosides ..................... 61 Domperidone ............................................... 26, 37 Doxazosin mesylate ........................................... 51 Dr Reddy’s Omeprazole................................ 41, 61 Dr Reddy’s Pantoprazole .............................. 35, 55 Dulcolax............................................................. 60 Duphalac ........................................................... 53 Duphaston ......................................................... 45 Dydrogesterone.................................................. 45 E EMLA................................................................. 53 Enalapril ....................................................... 22, 58 Enteral feed 1kcal/ml .......................................... 46 Enteral feed with fibre 1.5kcal/ml .................. 46, 48 Enteral feed with fibre 1 kcal/ml .......................... 46 Estradot 50 mcg ................................................ 21 Ethics Aspirin ..................................................... 36 Ethics Aspirin EC................................................ 35 Ethinyloestradiol with gestodene ......................... 42 Ethinyloestradiol with levonorgestrel ................... 45 Eurax ........................................................... 38, 44 F Femara .............................................................. 41 Femodene 28 ..................................................... 42 Fenpaed ....................................................... 36, 52 Ferodan ................................................. 29, 32, 51 Ferro-F-Tabs ................................................ 32, 51 Ferro-Gradumet.................................................. 32 Ferro-tab ...................................................... 32, 51 Ferrograd-Folic................................................... 33 Ferrous fumarate .......................................... 32, 51 Ferrous fumarate with folic acid .................... 32, 51 Ferrous gluconate with ascorbic acid .................. 32 Ferrous sulphate .................................... 29, 32, 51 Ferrous sulphate with folic acid .......................... 33 Fibersource HN .................................................. 46 Fibersource HN RTH........................................... 46 Flucloxacillin sodium .......................................... 42 Fludara............................................................... 41 Fludarabine phosphate ....................................... 41 Flumetasone pivalate .......................................... 21 Fluocortolone caproate with fluocortolone pivalate and cinchocaine ................................. 52 Fluorouracil Ebewe ........................... 23, 45, 52, 60 Fluorouracil sodium.......................... 23, 45, 52, 60 Fluox...................................................... 21, 36, 52 Fluoxetine hydrochloride ......................... 21, 36, 52 Fluvax ................................................................ 26 Foban .......................................................... 35, 52 Food thickener ................................................... 46 Fosamax ............................................................ 30 Fosamax Plus .................................................... 30 Furosemide .................................................. 45, 60 Fusidic acid.................................................. 35, 52 G Gaviscon ........................................................... 46 Gemcitabine Ebewe................................ 33, 37, 52 Gemcitabine hydrochloride ..................... 33, 37, 52 Gemzar .............................................................. 33 GenRx Moclobemide .......................................... 45 Glycerol ....................................................... 21, 37 Glycerol with paraffin and cetyl alcohol ............... 47 Gynol II .............................................................. 47 H healthE....................................... 21, 50, 52, 53, 56 Healtheries Iron with Vitamin C ........................... 32 Heparin sodium.................................................. 46 Herceptin ........................................................... 28 Hormone Replacement Therapy – Systemic........ 24 Hydrocortisone ............................................ 45, 61 Hydrocortisone butyrate ..................................... 41 Hydrocortisone with miconazole ......................... 36

Index

Pharmaceuticals and brands Hydrocortisone with natamycin and neomycin .... 61 Hydrogen peroxide ............................................. 47 Hydroxocobalamin ............................................. 41 I Ibuprofen ..................................................... 36, 52 Imigran .............................................................. 43 Impact Advanced ............................................... 57 Influenza vaccine................................................ 26 Influvac .............................................................. 26 Iodine with alcohol ............................................. 52 Ipratropium bromide ........................................... 53 Ipratropium Steri-Neb ......................................... 53 Irinotecan..................................................... 22, 58 Irinotecan-Rex.............................................. 22, 58 Isopropyl alcohol................................................ 53 Isosource 1.5............................................... 46, 48 Isosource HN ..................................................... 46 Isosource HN RTH ............................................. 46 Itraconazole ....................................................... 53 J Janola ................................................................ 47 K Kaletra ......................................................... 21, 53 Ketoconazole ..................................................... 46 Klacid ................................................................ 50 Klamycin............................................................ 50 L Lactulose ........................................................... 53 Lamivudine ........................................................ 39 Lamotrigine........................................................ 43 Laxofast 50 ............................................ 32, 60, 61 Laxofast 120 .......................................... 32, 60, 61 Lax-Tabs...................................................... 35, 49 Laxsol ................................................................ 61 Lemnis Fatty Cream HC...................................... 45 Letrozole ............................................................ 41 Levobunolol ....................................................... 53 Lignocaine ................................................... 23, 60 Lignocaine hydrochloride ................................... 53 Lignocaine hydrochloride with adrenaline............ 53 Lignocaine with prilocaine .................................. 53 Locacorten-Vioform ED’s ................................... 21 Locoid Crelo ...................................................... 41 Lopinavir with ritonavir ................................. 21, 53 Loraclear Hayfever Relief.............................. 37, 54 Lorapaed ..................................................... 37, 54 Loratadine.................................................... 37, 54 Losec Hp7 OAC ................................................. 46 Loxamine ..................................................... 36, 55 Lyderm .............................................................. 42 M Magnesium sulphate .......................................... 33 Malathion ........................................................... 29 Marcain ............................................................. 49 Marcain Heavy ................................................... 49 Marcain Isobaric ................................................ 49 Maxidex ............................................................. 51 MDS Quick Card .......................................... 39, 44 Medroxyprogesterone acetate....................... 54, 60 Megace........................................................ 39, 44 Megestrol acetate......................................... 39, 44 Mesna ............................................................... 54 Metabolic Mineral Mixture............................. 22, 48 Metformin hydrochloride .................................... 42 Methadone hydrochloride ................................... 54 Methatabs .......................................................... 54 Metoprolol - AFT CR........................................... 35 Metoprolol-AFT CR............................................. 54 Metoprolol succinate .................................... 35, 54 Micanol.............................................................. 41 Micreme H ......................................................... 36 Midwest ............................................................. 21 Mitomycin C ...................................................... 22 Mitozantrone ................................................ 37, 54 Mitozantrone Ebewe ..................................... 37, 54 Moclobemide ............................................... 45, 60 Motilium ...................................................... 26, 37 MultiADE............................................................ 21 Multiparin........................................................... 46 Multivitamins ............................................... 21, 46 N Nadolol .............................................................. 54 Naltrexone hydrochloride .............................. 31, 54 Nandrolone decanoate........................................ 22 Naproxen sodium ............................................... 55 Naropin .............................................................. 56 Navelbine ........................................................... 34 Neo-Naclex .................................................. 35, 44 Neostigmine methylsulphate ............................... 55 NeuroKare.......................................................... 21 Nilstat ................................................................ 55 Nizoral ............................................................... 46 Nonoxynol-9 ...................................................... 47 Norditropin SimpleXx 10mg ................................ 41 Norditropin SimpleXx 15mg ................................ 41 Norditropin SimpleXx 5mg .................................. 41 Norvasc ....................................................... 21, 49 Noten ................................................................. 42 Novasource Renal .............................................. 57 NovaSource Renal.............................................. 38

Index

Pharmaceuticals and brands Nutrini Energy RTH ............................................. 48 Nutrini RTH ........................................................ 48 Nystatin ............................................................. 55 O Octreotide (somatostatin analogue) .................... 27 Oestradiol .......................................................... 21 Oily cream ......................................................... 47 Omeprazole.................................................. 41, 61 Omeprazole, amoxycillin and clarithromycin ....... 46 Ondansetron hydrochloride................................. 55 Oral elemental feed 1kcal/ml............................... 38 Oral feed 1.5kcal/ml ..................................... 46, 48 Oral feed 1kcal/ml .............................................. 37 Oral supplement 1kcal/ml ................................... 37 Ortho ................................................................. 47 Ortho All-flex ...................................................... 47 Ortho Coil .......................................................... 47 Oxybutynin ......................................................... 55 Oxycodone hydrochloride ................................... 55 OxyNorm ........................................................... 55 P Paediatric enteral feed 1.5kcal/ml ....................... 48 Paediatric enteral feed 1kcal/ml .......................... 48 Paediatric Seravit ......................................... 21, 46 Pancreatic enzyme ............................................. 29 Panteston .................................................... 36, 45 Pantocid ............................................................ 55 Pantoprazole ................................................ 35, 55 Panzytrat............................................................ 29 Paracetamol with codeine .................................. 42 Paradex ............................................................. 44 Paroxetine hydrochloride .............................. 36, 55 Pedialyte - Bubblegum ....................................... 35 Pedialyte - Fruit .................................................. 35 Pedialyte - Plain ................................................. 35 Peptamen OS 1.0 ............................................... 57 Peptisoothe ........................................................ 56 Permethrin ......................................................... 42 Pharmacy Health ................................................ 61 Phenate ............................................................. 24 Phenergan ......................................................... 41 Phenoxymethylpenicillin (penicillin v) ............ 36, 55 Phenytoin sodium .............................................. 37 Pimafucort ......................................................... 61 Pindol ................................................................ 42 Pindolol ............................................................. 42 Pinorax ........................................................ 21, 51 Piperacillin sodium with tazobactam sodium ....... 61 Plavix ................................................................. 62 Polaramine......................................................... 43 Polytar Emollient ................................................ 47 Potassium chloride ............................................ 41 66 Potassium iodate ............................................... 21 Prantal ............................................................... 47 Prazosin hydrochloride ....................................... 55 Pregnancy tests - hcg urine .......................... 39, 44 Prilocaine hydrochloride ..................................... 56 Probenecid ........................................................ 40 Probenecid-AFT ................................................. 40 Promethazine hydrochloride ............................... 41 Propofol ............................................................. 58 Protein supplement ............................................ 22 Provera ........................................................ 54, 60 Provive 1%......................................................... 58 Q QV ..................................................................... 47 R Ranbaxy-Cefaclor......................................... 36, 50 Ranbaxy Amoxicillin ........................................... 43 Ranitidine hydrochloride ..................................... 56 Recovery Chocolate ........................................... 57 Recovery Vanilla ................................................ 57 Renal oral feed 2kcal/ml ..................................... 38 Resource Arginaid .............................................. 57 Resource Beneprotein .................................. 22, 57 Resource Diabetic ........................................ 37, 57 Resource Plus.............................................. 46, 48 Resource Thicken Up ......................................... 46 ReTrieve ............................................................ 21 Retrovir .............................................................. 62 ReVia ........................................................... 31, 54 Ridal ............................................................ 38, 58 Risperidone.................................................. 38, 58 Rivacol .............................................................. 40 Ropin ........................................................... 37, 56 Ropinirole hydrochloride............................... 37, 56 Ropivacaine hydrchloride with fentanyl ............... 56 Ropivacaine hydrochloride ................................. 56 S Salapin ........................................................ 37, 56 Salbutamol................................................... 37, 56 Sandostatin ........................................................ 27 Sandostatin LAR ................................................ 27 Serophene ............................................. 21, 24, 50 Silvazine ............................................................ 41 Silver sulphadiazine ............................................ 41 Sodium alginate ................................................. 46 Sodium citro-tartrate .......................................... 56 Sodium fluoride .................................................. 32 Sodium hypochlorite .......................................... 47 Somatropin ........................................................ 41 Sonaflam ........................................................... 55 Sorbolene with glycerine .................................... 56 Special food supplement .................................... 57

Index

Pharmaceuticals and brands Spironolactone ............................................. 35, 57 Spirotone ..................................................... 35, 57 Sporanox ........................................................... 53 Staphlex ............................................................. 42 Sumagran .......................................................... 43 Sumatriptan ....................................................... 43 Sunscreens, proprietary ..................................... 43 Sustagen Hospital Formula ........................... 37, 57 Suxamethonium chloride .................................... 57 Syrup (pharmaceutical grade) ............................ 57 T Tar with cade oil................................................. 47 Tasmar .............................................................. 27 Tazocin EF ......................................................... 61 Teniposide ......................................................... 43 Tenoxicam ......................................................... 60 Testosterone undecanoate................ 23, 36, 45, 60 Tolcapone .......................................................... 27 Topiramate......................................................... 62 Tramadol hydrochloride................................ 22, 59 Tranexamic acid ................................................. 62 Trastuzumab ...................................................... 28 Tretinoin ............................................................ 21 Trifeme .............................................................. 45 U Ultraproct ........................................................... 52 Ural.................................................................... 56 Uromitexan ........................................................ 54 V Vaxigrip ............................................................. 26 Vincristine sulphate ................................ 38, 40, 59 Vinorelbine ......................................................... 34 Vinorelbine Ebewe .............................................. 34 Vitamins ............................................................ 21 Vivonex Pediatric................................................ 57 Vivonex TEN................................................. 38, 57 Volibris .............................................................. 60 Voltaren SR ........................................................ 42 Vumon ............................................................... 43 W Wool fat with mineral oil ..................................... 43 X Xylocaine ........................................................... 53 Z Zidovudine (AZT) ................................................ 62 Zinc ................................................................... 47 Zincaps ........................................................ 33, 57 Zinc oxide .......................................................... 46 Zinc sulphate................................................ 33, 57 Zofran ................................................................ 55 Zofran Zydis ....................................................... 55

Index

Pharmaceuticals and brands

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 July 2010

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 July 2010 Cumulative for May, June and July 2010 Section H for April, May, June and July 2010 Contents Summary of PHARMAC decisions effective 1 July 2010 … 3 Topical…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.